

# CTAD 2013

Clinical Trials on Alzheimer's Disease

Montpellier '08 | Las Vegas '09 | Toulouse '10 | San Diego '11 | Monte Carlo '12

## Clinical Trials on Alzheimer's Disease

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Clinical Trials



**November 14-16, 2013**  
**San Diego**



MONTPELLIER and TOULOUSE EADC Centers  
European Alzheimer's Disease Consortium



Under the auspices of :



**UC San Diego**  
SCHOOL OF MEDICINE



# Welcome

## SCIENTIFIC COMMITTEE

Susan ABUSHAKRA (San Francisco)  
 Paul AISEN (San Diego)  
 Kaj BLENNOW (Molndal)  
 Merce BOADA (Barcelona)  
 Robert BRASHEAR (San Francisco)  
 Maria CARRILLO (Chicago)  
 Momy John DE LEON (New York)  
 Rachele DOODY (Houston)  
 Bruno DUBOIS (Paris)  
 Howard FELDMAN (Vancouver)  
 Nick FOX (London)  
 Giovanni B. FRISONI (Brescia)  
 Lutz FROELICH (Mannheim)  
 Serge GAUTHIER (Montreal)  
 Ezio GIACOBINI (Geneva)  
 Michael GRUNDMANN (San Diego)  
 Harald HAMPEL (Munich)  
 Takeshi IWATSUBO (Tokyo)  
 Zaven KHACHATURIAN (Washington DC)  
 Virginia LEE (Philadelphia)  
 Jean-Marc ORGOGOZO (Bordeaux)  
 Ronald PETERSEN (Minnesota)  
 Stephen SALLOWAY (Providence)  
 Philip SCHELTENS (Amsterdam)  
 Lon SCHNEIDER (Los Angeles)  
 Eric SIEMERS (Philadelphia)  
 Peter SNYDER (Rhode Island)  
 Reisa SPERLING (Boston)  
 Yaakov STERN (New York)  
 Jacques TOUCHON (Montpellier)  
 John TROJANOWSKI (Philadelphia)  
 Bruno VELLAS (Toulouse)  
 Michael W. WEINER (San Francisco)  
 Gordon WILCOCK (Oxford)  
 Bengt WINBLAD (Stockholm)

## ORGANIZING COMMITTEE

Paul AISEN  
 Jacques TOUCHON  
 Bruno VELLAS  
 Michael WEINER

## CONGRESS SECRETARIAT

ANT Congrès  
 E-mail : [ctad@ant-congres.com](mailto:ctad@ant-congres.com)  
 Ph : + 33 4 67 10 92 23

*Dear Colleague,*

We are proud to present our program for *the 6th annual conference Clinical Trials for Alzheimer's Disease CtaD 2013 in San Diego, CA – USA on November 14-16, 2013.*

*This year the CtaD conference will relate experiences from international teams covering every stage of clinical trials in AD. From animal models to human trials, CtaD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, Down syndrome and AD as well as ethical issues and methodological considerations.*

*Again this year CTAD is the perfect opportunity to exchange views with your peers on the difficulties and challenges of Alzheimer's disease and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD research and clinical trial teams. UC San Diego School of Medicine reviewed and awarded CtaD 2013 with 18 AMA PRA Category 1 Credits™ in compliance with ACCME essentials and Standards and CME policies and procedures.*

*We are very happy to welcome you to CTAD 2013 !*

**Paul Aisen, MD**  
 University of California San Diego (UCSD)

**Jacques Touchon, MD, PhD**  
 University Hospital of Montpellier, France

**Bruno Vellas, MD, PhD**  
 University Hospital of Toulouse, France

**Michael Weiner, MD**  
 University of California San Francisco (UCSF)



# Keynote speakers



**Paul S. Aisen M.D.** is the Director of the Alzheimer's Disease Cooperative Study (ADCS) and Professor in the Department of Neurosciences at UCSD. He has been conducting therapeutic research on Alzheimer's disease for the past two decades. Dr. Aisen joined the faculty at Georgetown University in 1999 as Professor in the Departments of Neurology and Medicine and that year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer's disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers of AD and designed and directed multicenter therapeutic trials. He became Vice Chair of the Department of Neurology at Georgetown in 2004. Following the tragic death of ADCS founder Leon Thal, M.D. in early 2007, Dr. Aisen relocated to UCSD to assume the position of Director of the ADCS and Professor of Neurosciences.



**Jeffrey Cummings, MD, ScD**, is Director of Cleveland Clinic Lou Ruvo Center for Brain Health and the Camille and Larry Ruvo Chair for Brain Health. Dr. Cummings' research and leadership in the field of Alzheimer's disease have been recognized with many awards, including the Henderson Award of the American Geriatrics Society, the Research Award of the John Douglas French Alzheimer's Research Foundation, and the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association. Dr. Cummings is the author of the Neuropsychiatric Inventory (NPI), the most commonly used tool for characterizing behavioral disturbances in dementia syndromes and for measuring the effect of therapies on neuropsychiatric symptoms in Alzheimer's disease and other dementias.



**Serge Gauthier, MD, FRCPC - Dr. Gauthier** is currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital. He did his medical training at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007). Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer's disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.



**David M. Holtzman**, is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders at the Washington University School of Medicine in St. Louis, MO – USA. His major interest is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS particularly as these mechanisms may relate to Alzheimer's disease (AD) and injury to the developing brain.



## Keynote speakers



**William C. Mobley** is a Distinguished Professor and Chair of the Department of Neurosciences at UCSD. He also serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment.

Dr. Mobley has a distinguished record of academic achievement and is considered one of the most outstanding academic neurologists in the US. He has an international reputation for his research on degenerative disease of the central nervous system as well as being a leader in translational medicine, bridging clinical and basic science in various areas. More



**Ronald C. Petersen, MD, PhD** is the Director of the Mayo Alzheimer's Disease Research Center and has an interest in clinical research involving aging, mild cognitive impairment, dementia, Alzheimer's Disease, and neuroimaging. The Mayo Alzheimer's Disease Research Center is part of a network of 28 centers around the country sponsored by the National Institute on Aging. This center operates in Rochester, MN and Jacksonville, FL. In addition, Dr. Petersen has a National Institute on Aging funded registry on aging and dementia in Rochester. This is a longitudinal project on clinical, epidemiological, genetic, biomarker,

imaging, and neuropathological aspects of aging and very early cognitive impairment. His team is developing models for predicting a subsequent cognitive impairment in normal elderly persons. A great deal of his work has focused on mild cognitive impairment as an intermediate stage between normal aging and Alzheimer's disease. Recently, he has begun a project funded by the Mayo Foundation investigating various aspects of successful cognitive aging in the community. He also studies non-Alzheimer's disease dementias such as frontotemporal dementia, dementia with Lewy bodies and vascular dementia.



**Dr. Eric Reiman** is chief executive officer of Banner Research, executive director of Banner Alzheimer's Institute, clinical director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), professor of psychiatry at the University of Arizona, and director of the Arizona Alzheimer's Consortium. His research interests include brain imaging, genomics and their application to the study of normal and abnormal human behaviors; the early detection, tracking and study of Alzheimer's disease; and the accelerated evaluation of presymptomatic Alzheimer's disease treatments.

Dr. Reiman is internationally recognized for his contributions to the fields of brain imaging, the behavioral neurosciences and the presymptomatic study of Alzheimer's disease.

# Contents

<b>CTAD 2013 Program .....</b>	<b>p. 4 - 17</b>
Program at a glance .....	p. 4 - 5
Thursday, November 14 <sup>th</sup> .....	p. 6 - 10
Friday, November 15 <sup>th</sup> .....	p. 11 - 15
Saturday, November 16 <sup>th</sup> .....	p. 16 - 17
<b>Poster presentations .....</b>	<b>p. 18 - 28</b>
<b>General information .....</b>	<b>p. 29</b>
<b>Continuing Medical Education .....</b>	<b>p. 30 - 31</b>
<b>Faculty List .....</b>	<b>p. 32 - 33</b>
<b>Disclosure summary .....</b>	<b>p. 34 - 38</b>
<b>Acknowledgements .....</b>	<b>p. 38</b>





# Program at a glance

## Thursday, November 14<sup>th</sup>

8.00 - 8.15 a.m WELCOME BY THE ORGANIZING COMMITTEE

*California Ballroom ABC*

8.15 - 8.45 a.m **OPENING KEYNOTE**

*California Ballroom ABC*

Toward effective Alzheimer's therapy : progress and collaboration

8.45 - 10.00 a.m **Symposium 1**

*California Ballroom ABC*

Clinical trials in early stage Alzheimer's disease: Current methodological and regulatory considerations

10.00 - 10.30 a.m

*California Ballroom ABC*

**KEYNOTE**

When to Treat: Biomarkers in MCI and Pre-Clinical AD

*Coffee Break and poster sessions - San Diego Ballroom*

11.00 - 12.45 p.m

**PARALLEL SESSIONS: ORAL COMMUNICATIONS**

DATA FROM CLINICAL TRIALS

*California Ballroom AB*

IMAGING IN CLINICAL TRIALS ON AD

*California Ballroom C*

*Lunch Break and poster sessions - San Diego Ballroom*

1.45 - 3.00 p.m

**PARALLEL SESSIONS: ORAL COMMUNICATIONS**

STUDY DESIGN FOR CLINICAL TRIALS

*California Ballroom AB*

PRECLINICAL STUDIES IN ALZHEIMER'S DISEASE

*California Ballroom C*

3.00 - 3.45 p.m

**PARALLEL SESSIONS: ORAL COMMUNICATIONS**

COGNITIVE AND IMAGING ASSESSMENT FOR CLINICAL TRIALS

*California Ballroom AB*

PET IMAGING OF TAU PATHOLOGY

*California Ballroom C*

*Coffee Break and poster sessions - San Diego Ballroom*

4.15 - 4.45 p.m

*California Ballroom ABC*

**KEYNOTE**

The New Era in Alzheimer's Prevention Research

4.45 - 6.00 p.m

*California Ballroom ABC*

**Symposium 2**

Rethinking the Way to Conduct Drug Trials in Alzheimer 's disease

6.30 p.m

Bus departure to the Welcome Reception

*Lobby of the Westin Gaslamp Quarter*

7.00 p.m

Welcome Reception at the Omni Hotel

## Friday, November 15<sup>th</sup>

8.30 - 9.00 a.m

*California Ballroom ABC*

### KEYNOTE

AD and Down's syndrome

9.00 - 10.15 a.m

*California Ballroom ABC*

### Symposium 3

Agitation and Aggression in AD: A New Target for Drug Development

*Coffee Break and poster sessions - San Diego Ballroom*

10.45 - 12.15 p.m

### PARALLEL SESSIONS: ORAL COMMUNICATIONS

COMPOSITE OUTCOMES FOR CLINICAL TRIALS

*California Ballroom AB*

NEUROIMAGING PET FOR CLINICAL TRIALS

*California Ballroom C*

*Lunch Break and poster sessions - San Diego Ballroom*

1.15 - 3.15 p.m

### PARALLEL SESSIONS: ORAL COMMUNICATIONS

TREATMENT ASSESSMENT FOR CLINICAL TRIALS

*California Ballroom AB*

BIOMARKERS FOR CLINICAL TRIALS

*California Ballroom C*

*Coffee Break and poster sessions - San Diego Ballroom*

3.45 - 4.15 p.m

*California Ballroom ABC*

### KEYNOTE

Designing drug trials taking into account neuropsychiatric symptoms of AD

4.15 - 5.30 p.m

*California Ballroom ABC*

### Symposium 4

Internet screening of cognition as a method for recruiting to clinical trials in prodromal Alzheimer's disease

5.30 - 6.00 p.m

*California Ballroom ABC*

### KEYNOTE

Ethical issues in AD prevention trials: genetics, biomarkers and treatment risk

## Saturday, November 16<sup>th</sup>

8.00 - 8.30 a.m

*California Ballroom AB*

### KEYNOTE

Novel immunotherapy approaches

8.30 - 10.00 a.m

### PARALLEL SESSIONS

#### Symposium 5

Metabolic dysregulation in the Alzheimer brain: challenges and opportunities

*California Ballroom AB*

#### ORAL COMMUNICATIONS

8.30 - 9.00 a.m

BIOMARKERS FOR CLINICAL TRIALS

9.00 - 10.00 a.m

PRECLINICAL STUDIES IN AD

*California Ballroom C*

*Coffee Break and poster sessions - San Diego Ballroom*

10.30 - 11.45 a.m

*California Ballroom AB*

#### Symposium 6

CSF biomarkers in clinical trials

# CTAD 2013 Program

## Thursday, November 14<sup>th</sup>

8.00 a.m	<p><i>California Ballroom ABC</i></p> <p><b>Welcome by the organizing committee and presentation of the CtaD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research</b>, to Russell Katz MD, former Director, Division of Neurology Products, U.S. Food and Drug Administration Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner</p>	
8.15 a.m	<p><b>OPENING KEYNOTE</b> - <i>California Ballroom ABC</i></p> <p><b>Toward effective Alzheimer's therapy: progress and collaboration</b> Paul Aisen, MD, <i>University of California at San Diego, USA</i></p>	
8.45 a.m	<p><b>SYMPOSIUM 1</b> - <i>California Ballroom ABC</i></p> <p>Clinical trials in early stage Alzheimer's disease: Current methodological and regulatory considerations Moderators: John Harrison PhD, <i>Metis Cognition Ltd, Kilmington Common, Wiltshire, UK</i></p> <ol style="list-style-type: none"> <li>1. What are we trying to measure in preclinical and prodromal Alzheimer's disease? Lon Schneider MD, MS. <i>Keck School of Medicine of the University of Southern California, USA</i></li> <li>2. How can changes in cognitive function be measured in therapeutic trials in preclinical AD? Keith Wesnes PhD, <i>Bracket Global, Goring UK &amp; Swinburne University, Melbourne, Australia</i></li> <li>3. A regulatory perspective on therapeutic trials in early stage Alzheimer's disease Nicholas Kozauer MD, <i>Food and Drug Administration, Silver Spring, MD, USA</i></li> </ol>	
10.00 a.m	<p><b>KEYNOTE</b> - <i>California Ballroom ABC</i></p> <p>Moderator : Bruno vellas</p> <p><b>When to treat: Biomarkers in MCI and pre-clinical AD</b> Ronald C. Petersen, M.D., Ph.D, <i>Mayo Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA</i></p>	
10.30 a.m	<p><b>Coffee Break and poster sessions</b> - <i>San Diego Ballroom</i></p>	
11.00 - 12.45 p.m	<p><b>11.00 a.m - 12.45 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS</b></p>	
	<p><i>California Ballroom AB</i></p> <p><b>DATA FROM CLINICAL TRIALS</b></p>	<p><i>California Ballroom C</i></p> <p><b>IMAGING IN CLINICAL TRIALS ON AD</b></p>
11.00 a.m	<p><b>DATA FROM CLINICAL TRIALS</b> - <i>California Ballroom AB</i></p> <p>Moderators : Jeffrey Cummings, Serge Gauthier</p> <p><b>OC1</b> - Stereotactic gene delivery of NGF (via AAV2-NGF) in AD patients: Safe &amp; effective targeting to degenerating cholinergic neurons Raymond T. Bartus, PhD (1,2), Tiffany L. Baumann, BS (1,3), Roy A.E. Bakay, MD (4), Jeffrey M. Ostrove, PhD (1), Joao Siffert, MD (1,5), Adam S. Fleisher, MD (6,7), Christopher D. Herzog, PhD (1), David Barba, MD (6), Mary Pay, APN (6), David P. Salmon, MD (6), Yaping Chu, MD (4), Jeffrey H. Kordower, PhD (4), Kathie Bishop, PhD (1.3), David Keator, PhD (8), Steven Potkin, MD (8), Michael S. Rafii, MD (6) (1) Ceregene, Inc., San Diego, CA, USA, (2) RTBioconsultants, Inc, San Diego, CA, USA, (3) Isis Pharmaceuticals, Carlsbad, CA, USA, (4) Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA, (5)Avanir Pharmaceuticals, Alijo Viejo, CA, USA; (6) Department of Neurosciences, University of California, San Diego, CA, USA, (7) Banner Alzheimer's Institute, Phoenix, AZ, USA, (8) University of California, Irvine, CA, USA</p>	
11.15 a.m	<p><b>OC2</b> - Improvements to attention and verbal episodic memory with memantine in Parkinson's disease dementia and dementia with Lewy bodies Keith A. Wesnes (1,2,3), Clive Ballard (5), Elisabet Londos (6) (1) Bracket Global, Goring on Thames, UK, (2) Department of Psychology, Northumbria University, Newcastle, UK, (3) Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia, (5) Wolfson Centre for Age Related Diseases, Institute of Psychiatry, King'sCollege London, London, UK, (6) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden</p>	
11.30 a.m	<p><b>OC3</b> - Baseline memory problems associate with clinical impairments eight years later: centralized follow-up in the PREADVICE trial Richard Kryscio, PhD (1,2), Erin Abner, PhD (2), Allison Caban-Holt, PhD (2,3), Melissa Mathews, PhD (4), Frederick Schmitt, PhD (2,3,4,5) (1) Departments of Statistics and Biostatistics, University of Kentucky, Lexington, KY, USA, (2) Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA, (3) Department of Behavioral Sciences, University of Kentucky, Lexington, KY, USA, (4) Department of Neurology, University of Kentucky, Lexington, KY, USA, (5) Department of Psychiatry, University of Kentucky, Lexington, KY, USA</p>	



## Thursday, November 14<sup>th</sup>

### DATA FROM CLINICAL TRIALS - California Ballroom AB

- 11.45 a.m **OC4** - Bayesian longitudinal modeling on placebo data from Alzheimer's disease clinical studies  
Yun-Fei Chen (1), Richard Mohs (1), Ying Ding (2), Paul Aisen (3), Ronald G. Thomas (3)  
 (1) Eli Lilly and Company, USA, (2) University of Pittsburg, USA, (3) University of California, San Diego, USA
- 12.00 p.m **OC5** - Mild versus moderate stage of Alzheimer's disease three-year outcomes of cholinesterase inhibitor therapy in a routine clinical setting  
Carina Wattmo, RN, BSc, PhD, Lennart Minthon, MD, PhD, Åsa K. Wallin, MD, PhD  
 Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, LundUniversity, Malmö, Sweden
- 12.15 p.m **OC6** - The NIA ASPREE trial— aspirin in reducing events in the elderly  
Anne M. Murray, MD (1), Richard H Grimm, MD, PhD (2), Brenda Kirpach (2), John McNeil, MD, PhD (3), Robyn Woods, PhD (3), Mark Nelson, MD, PhD (3), Elsdon Storey, MD (3), A. Tonkin, MD (3), Raj Shah, MD (4)  
 (1) Department of Medicine and Geriatrics, Hennepin County Medical Center, Minneapolis, MN USA, (2) Berman Center for Clinical Trials, Minneapolis Medical Research Foundation and University of Minnesota, Minneapolis, MN, USA, (3) Monash University, Department of Epidemiology & Preventive Medicine, Melbourne, Australia, T.Lockett, Preventative Health National Research Flagship, Commonwealth Scientific and Industrial Research Organisation (CSIRO) Molecular and Health Technologies, North Ryde, NSW, Australia, (4) Rush Alzheimer's disease center, Chicago, IL, USA
- 12.30 p.m **OC7** - A first-in-human study of BAN2401, a novel monoclonal antibody against amyloid- $\beta$  protofibrils  
Veronika Logovinsky, MD, PhD (1), Robert Lai, MA, MB BChir, PhD, MRCP, FPM (2), Kenan Gu, PhD (1), Yanke Yu, PhD (3), Chad J. Swanson, PhD (1), Andrew Satlin, MD (1)  
 (1) Eisai Inc. Woodcliff Lake, NJ, USA, (2) Eisai Ltd. London, UK, (3) Eisai Inc. Andover, MA, USA

### IMAGING IN CLINICAL TRIALS ON AD - California Ballroom C

Moderators : Mark Mintun, Joyce Suhy

- 11.15 a.m **OC8** - Increasing role of imaging in Alzheimer disease trials: issues and risk management strategies  
Kohkan Shamsi MD, PhD  
 Founder and Principal, RadMD, New York, NY, USA
- 11.30 a.m **OC9** - Performance metrics for two large phase III Alzheimer's disease clinical trials; an MRI perspective  
Rahul Peethala, Joyce Suhy, Joonmi Oh  
 Synarc Inc, Newark, NJ, USA
- 11.45 a.m **OC10** - Effects of ELND005 (Scylloinositol) long term treatment on Amyloid related imaging abnormalities (ARIA) in Phase 2 AD studies  
Anton P. Porsteinsson (1), Christopher VanDyck (2), Matthias Kurth (3), Sheila O'Mahony (3), Aarti Verma (3), Gerald Crans (3), J. Patrick Kesslak (3), Susan Abushakra (3)  
 (1) Department of Psychiatry, University of Rochester, (2) Department of Neurology, Yale University, (3) Elan Pharmaceuticals, Inc., Global Development, San Francisco CA
- 12.00 p.m **OC11** - MRI findings in patients on placebo in phase 3 clinical trials of mild-moderate Alzheimer's disease  
Ketter N, Brashear, HR, Miaux, Y, Purcell, DD, Barkhof, F, Gass, A, M, Morris, K, Guenzler, V, Arrighi, HM  
 Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA - USA
- 12.15 p.m **OC12** - Preliminary analysis of baseline FDG PET in PET substudies of Phase 3 i.v. bapineuzumab trials in mild to moderate AD: Patterns and severity of regional brain hypometabolism and relationship to fibrillary amyloid burden measured by 11C-PiB PET and clinical outcomes  
Schmidt ME, MD (1), Gregg K, PhD (1), Margolin R, MD (1), Lukic AS, PhD (2), Andrews RD, MS (2), Matthews DC, MS, MBA (2), Wernick MN, PHD (2), Strother SC, PHD (2), Brashear R, MD (1), Liu E, PhD (1)  
 (1) Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA, USA, (2) ADMdx, Chicago, IL, USA
- 12.30 p.m **OC13** - Longitudinal LEAP is equivalent to semi-automatic VBSI on ADNI data in terms of group separation  
Katherine R. Gray, PhD (1,2), Robin Wolz, PhD (1,2), Mark Austin, PhD (1), Daniel Rueckert, PhD (2), Kate McLeish, PhD (1), Derek Hill, PhD (1)  
 (1) IXICO Ltd, London, United Kingdom, (2) Department of Computing, Imperial College London, United Kingdom
- 12.45 p.m **Lunch Break and poster sessions** - San Diego Ballroom

# CTAD 2013 Program

Thursday, November 14<sup>th</sup>

## 1.45 p.m - 3.00 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS

1.45 - 3.00 p.m

California Ballroom AB  
**STUDY DESIGN FOR CLINICAL TRIALS**

California Ballroom C  
**PRECLINICAL STUDIES IN ALZHEIMER'S DISEASE**

### STUDY DESIGN FOR CLINICAL TRIALS - California Ballroom AB

Moderators : Susan Abushakra, Lon Schneider

- 1.45 p.m **OC14** - A pharmacogenetics supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease: An update  
Allen D. Roses, MD (1,2), Kathleen A. Welsh-Bohmer, PhD (2), Daniel K. Burns, PhD (1), Carl Chiang, PhD (1), Donna G. Crenshaw, PhD (1,2), Michael W. Lutz, PhD (1,2), Craig A. Metz, PhD (1), Ann M. Saunders, PhD (1,2), Deborah Yarbrough, MS, MBA (3), Stephen Brannan, MD (3), Kumar Budur, MD, MS (3)  
(1) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, (2) Duke Bryan ADRC, Durham, NC, USA, (3) Takeda Global Research & Development Center, Inc., Deerfield, IL, USA
- 2.00 p.m **OC15** - Evidence that compromised neurogenesis in Alzheimer's disease is linked to APOE  $\epsilon$ 4 status and CSF A $\beta$ 42  
Keith A. Wesnes PhD (1,2), Peter Annas PhD (3), Hans Basun MD PhD (4), Kaj Blennow MD PhD (5)  
(1) Bracket Global, Goring on Thames, UK, (2) Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia, (3) Astra Zeneca, R&D Södertälje, Sweden, (4) BioArctic Neuroscience AB, Sweden, (5) Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 2.15 p.m **OC16** - Imputation of amyloid status in a mild AD clinical trial cohort using a structural MRI based shape variation signature  
Duygu Tosun, PhD (1), Peng Yu, PhD (2), Peter Castelluccio, MS (2), Yun-Fei Chen, PhD (2), Joyce Suhy, PhD (2), Eric R Siemers, MD (2), Adam J Schwarz, PhD (2), Michael Weiner, MD (1)  
(1) Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA, (2) Eli Lilly and Company, Indianapolis, IN, USA, (3) Synarc Inc, San Francisco, CA, USA
- 2.30 p.m **OC17** - Anti-amyloid therapies: influence of ApoE genotypes and CSF A $\beta$  levels on inclusion of patients  
Julien Dumurgier MD PhD (1), Jean Louis Laplanche PharmD PhD (2), Jacques Hugon MD PhD (1), Claire Paquet MD PhD (1)  
(1) Memory Center Lariboisiere Hospital Paris France, (2) Department of Biochemistry Lariboisiere Hospital Paris, France
- 2.45 p.m **OC18** - A better way to measure the progress of pre-symptomatic AD?  
John Breitner, MD, MPH  
McGill University Faculty of Medicine, Centre for Studies on Prevention of AD investigators, Montreal, Québec, Canada

### PRECLINICAL STUDIES IN ALZHEIMER'S DISEASE - California Ballroom C

Moderators : David Holtzman, Zaven Kachaturian

- 1.45 p.m **OC19** - New cellular models for drug discovery in Alzheimer's disease  
Jordan L. Holtzman, M.D., Ph.D. (1,2,3)  
(1) Departments of Pharmacology, (2) Medicine, (3) and Division of Environmental Health Sciences, University of Minnesota, Minneapolis, MN, USA
- 2.00 p.m **OC20** - Brain structural connectivity in two mouse models of Alzheimer's disease: an in vivo diffusion study  
Moira Marizzoni, PhD (1), Edoardo Micotti, PhD (2), Alessandra Paladini, MS (2), Claudia Balducci, PhD (2), Anna Caroli, PhD (1,3), Sophie Dix, PhD (4), Christian Czech, PhD (5), Laurence Ozmen, PhD (5), Jill C. Richardson, PhD (6), Gianluigi Forloni, PhD (2), Giovanni Frisoni, MD (1), on behalf of the PharmaCog Consortium presented by Martina Bocchetta, MS  
(1) Laboratory of Epidemiology and Neuroimaging, IRCCS Fatebenefratelli, Brescia, Italy, (2) Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milano, Italy, (3) Biomedical Engineering Department, Mario Negri Institute for Pharmacological Research, Bergamo, Italy, (4) Eli Lilly, Lilly Research Centre, Windlesham, Surrey, UK, (5) CNS Research, Hoffmann-La Roche AG, Basel, CH, (6) GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK

## Thursday, November 14<sup>th</sup>

### PRECLINICAL STUDIES IN ALZHEIMER'S DISEASE - California Ballroom C

- 2.15 p.m **OC21** - A novel peptide derived from the Cdk5 regulator p35, crosses blood brain barrier and rescues phenotypes of Alzheimer's disease model mice  
Harish C. Pant, MD, PhD, CPR Division, NINDS, NIH, Bethesda, MD USA
- 2.30 p.m **OC22** - Does atorvastatin or telmisartan alter CSF memantine kinetics? A study in normal and STZ-induced rat model of Alzheimer  
Omnia Nayel, MD, PhD (1), Maha El-Tohamy, PhD (2), Wessam El Hadidy, MD, PhD (3)  
(1) Pharmacology department, Faculty of Medicine, King Saud University, Riyadh, KSA, (2) Chemistry department, Faculty of Science, King Saud University, Riyadh, KSA, (3) Pharmacology department, Medical Research Institute, Alexandria University, Alexandria, Egypt
- 2.45 p.m **OC23** - MultiTEP platform based AD vaccine immunogenic in rabbits and monkeys  
Hayk Davtyan, PhD (1), Irina Petrushina, PhD (2), Claire F. Evans, PhD (3), Armine Hovakimyan (1), Arpine Davtyan (1), Drew Hannaman (3), David H.Cribbs, PhD (2,4), Anahit Ghochikyan, PhD (1), Michael G.Agadjanyan, PhD (1,2)  
(1) Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA, (2) Institute for Memory Impairments and Neurological Disorders, University of California at Irvine, Irvine CA, USA, (3) Ichor Medical Systems, San Diego, CA, USA, (4) Department of Neurology, University of California at Irvine, Irvine, CA, USA

### 3.00 p.m - 3.45 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS

3.00 - 3.45 p.m

California Ballroom AB

**COGNITIVE AND IMAGING ASSESSMENT FOR CLINICAL TRIALS**

California Ballroom C

**PET IMAGING OF TAU PATHOLOGY**

### COGNITIVE AND IMAGING ASSESSMENT FOR CLINICAL TRIALS - California Ballroom AB

Moderators : Michael Donohue, Lisa Mosconi

- 3.00 p.m **OC24** - Improving measurement of change and demonstrating clinical meaningfulness in Alzheimer's clinical trials  
William R. Shankle, MS, MD (1,4), Junko Hara, PhD (1,2), Dennis Fortier, MS, MBA (1)  
(1) Medical Care Corporation, Newport Beach, CA, (2) Shankle Clinic, Newport Beach, CA, (3) Memory and Cognitive Disorders Program, Hoag Neurosciences Institute, Newport Beach, CA, (4) Dept. of Cognitive Sciences, University of California, Irvine, CA
- 3.15 p.m **OC25** - Biomarkers and Cognition in Amyloid-positive and Amyloid-negative ADNI MCI Subjects: Implications for AD Therapeutic Trials  
Richard A Margolin MD (1), Randolph D Andrews MS (2), Michael Ropacki PhD (1), Ana S Lukic PhD (2), Stephen Salloway MD (3), Reisa Sperling MD, MMSc (4), H Robert Brashear MD (1), Mark E Schmidt MD (6), Enchi Liu PhD (1), Dawn C Matthews MS, MBA (2) for the Alzheimer's Disease Neuroimaging Initiative  
(1) Janssen Alzheimer Immunotherapy LLC, South San Francisco, CA, USA; (2) ADM Diagnostics LLC, Chicago, IL, USA; (3) Butler Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA; (4) Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, MA, USA; (6) Janssen Research and Development, Beerse, Belgium
- 3.30 p.m **OC26** - Cognitive decline, hippocampal atrophy and amyloid accumulation in preclinical and prodromal AD: Clinical trial implications  
Paul Maruff, PhD (1,2,6), Yen Ying Lim (2), Robert H.Pietrzak (3), Kathryn A.Ellis (4,6), Colin L.Masters (2,4,6), Christopher C.Rowe (5,6)  
(1) CogState Ltd, (2) The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, (3) Yale University Medical School, (4) The University of Melbourne, (5) Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia, (6) For the AIBL Research Group

# CTAD 2013 Program

## Thursday, November 14<sup>th</sup>

### PET IMAGING OF TAU PATHOLOGY - California Ballroom C

- 3.00 p.m. **OC27** - PET imaging of tau pathology in patients with Alzheimer's disease using 18F-THK5117  
Nobuyuki Okamura (1), Shozo Furumoto (2), Ryuichi Harada (1), Katsutoshi Furukawa (3), Aiko Ishiki (3), Naoki Tomita (3), Ren Iwata (2), Manabu Tashiro (2), Kazuhiko Yanai (1,2), Hiroyuki Arai (3), Yukitsuka Kudo (4)  
*(1) Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan, (2) Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan, (3) Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, (4) Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan*
- 3.15 p.m. **OC28** - Tau PET, amyloid PET and cognitive performance  
Keith A Johnson, M.D., J. Alex Becker, Ph.D., Dorene Rentz, Psy.D., Aaron Schultz, Ph.D., Marlie Philiossaint, Jonathan Alverio, Kelly Judge, Neil Vasdev, Ph.D., Thomas Brady, M.D., Bradley Hyman, M.D., Ph.D., Reisa A. Sperling, M.D  
*Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA*
- 3.30 p.m. **OC29** - Preliminary Analysis of PET Scans using the Tau Imaging Tracer [F-18]-T807 (AV-1451) in Alzheimer's Disease  
Mark Mintun (1), Abhinav Joshi (1), Sergey Shcherbinin (2), Adam J. Schwarz (2), Ming Lu (1), Michael Pontecorvo (1), Michael Devous (1), Daniel Skovronsky (1), Hartmuth Kolb (1)  
*(1) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, (2) Eli Lilly & Co, Indianapolis, IN*
- 3.45 p.m. **Coffee Break and poster sessions** - San Diego Ballroom

4.15 p.m. **KEYNOTE** - California Ballroom ABC  
Moderator : Mike Weiner  
**The New Era in Alzheimer's Prevention Research**  
Eric Reiman MD - Executive Director, Banner Alzheimer's Institute, Phoenix, AZ - USA

4.45 p.m. **SYMPOSIUM 2** - California Ballroom ABC  
Rethinking the way to conduct drug trials in Alzheimer's disease  
Moderators: Bruno Vellas (*Toulouse*), Jeffrey Cummings (*Las Vegas*), Michael Weiner (*San-Francisco*), Jacques Touchon (*Montpellier*)

1. A historical analysis of AD drug trials from 2000 to 2013  
Valérie Legrand, PharmD, *ICON, Paris, France*
2. Changes needed and consequences conducting drug trials from symptomatic to disease-modifying trials  
Julien Delrieu, MD *Toulouse Alzheimer's Disease Research Clinical Center, Gérontopôle, Toulouse, France*
3. New models of clinical trials for Alzheimer's disease  
Jeffrey Cummings, MD *Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas Nevada, Cleveland, Ohio and Weston, Florida*
4. Center for drug trials on AD, today limits and perspectives  
Pierre-Jean Ousset, MD, *CenGeps Alzheimer Drug Trial Network, Gerontopole, Toulouse France*
5. Using the Internet for recruiting, assessing, and monitoring subjects in AD prevention trials: The Brain Initiative  
Mike Weiner, MD, *University of California at San Francisco, UCSF*

6.30 p.m. Bus departure to the Welcome Reception - Lobby of the Westin Gaslamp

7.00 p.m. Welcome Reception at the Omni San Diego Hotel

## Friday, November 15<sup>th</sup>

8.30 a.m	<b>KEYNOTE</b> - <i>California Ballroom ABC</i> Moderator : Paul Aisen <b>AD and Down's syndrome</b> William Mobley, <i>Professor and Chair, Department of Neurosciences, University of California at San Diego, CA – USA</i>	
9.00 a.m	<b>SYMPOSIUM 3</b> - <i>California Ballroom ABC</i> Agitation and aggression in AD: a new target for drug development Susan Abushakra MD (1), Sandrine Andrieu MD (2), Gene Kinney PhD (3), David Sultzer MD (4), Anton P. Porsteinsson MD (5), Constantine Lyketsos MD (6) (1) <i>Elan Pharmaceuticals, San Francisco CA</i> , (2) <i>University of Toulouse, France</i> , (3) <i>Prothena Biosciences, San Francisco CA</i> , (4) <i>University of California Los Angeles, Los Angeles CA</i> , (5) <i>University of Rochester, Rochester, NY</i> , (6) <i>Johns Hopkins University, Baltimore MD</i>	
10.15 a.m	<i>Coffee Break and poster sessions - San Diego Ballroom</i>	
10.45 - 12.15 p.m	<b>10.45 a.m - 12.15 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS</b>	
	<i>California Ballroom AB</i> <b>COMPOSITE OUTCOMES FOR CLINICAL TRIALS</b>	<i>California Ballroom C</i> <b>NEUROIMAGING PET FOR CLINICAL TRIALS</b>
	<b>COMPOSITE OUTCOMES FOR CLINICAL TRIALS</b> - <i>California Ballroom AB</i> Moderators : John Harrison, Suzanne Hendrix	
10.45 a.m	<b>OC30</b> - An empirical model of the natural progression of clinical measures of Alzheimer disease <u>Suzanne Hendrix</u> , PhD, Stephanie Stanworth, MS, Noel Ellison, MS <i>Pentara Corporation, Salt Lake City, UT, USA</i>	
11.00 a.m	<b>OC31</b> - Composites v2.0: newer measures + earlier population = improved composite <u>Michael T. Ropacki</u> , PhD (1,2), Suzanne B.Hendrix, PhD (3), Daniel Ryon Seichepine, PhD (4), Robert Stern, PhD (4) (1) <i>Janssen Research &amp; Development, LLC, San Francisco, CA,USA</i> , (2) <i>Neurology Department, Loma Linda University, Salt Lake City, UT, USA</i> , (4) <i>Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA</i>	
11.15 a.m	<b>OC32</b> - Optimal composite scale endpoints for clinical trials in mild cognitive impairment and pre-clinical Alzheimer's disease <u>M. Colin Ard</u> , PhD (1), Steven D. Edland, PhD (1,2) (1) <i>Department of Neurosciences and (2) Department of Family Preventive Medicine Division of Biostatistics, University of California, San Diego, CA, USA</i>	
11.30 a.m	<b>OC33</b> - Brief online computerized cognitive battery as a screening tool for clinical trials in MCI and mild dementia due to AD <u>Bruce Alcala</u> , PhD (1), Paul Maruff, PhD (3), Judith Jaeger, PhD (4), Michelle Gee, PhD (5), Andrew Satlin, MD (1) (1) <i>Eisai Inc, Woodcliff Lake, NJ, USA</i> , (3) <i>Cog State Ltd., Melbourne, Australia</i> , (4) <i>Cog State Inc., New Haven, CT, USA</i> , (5) <i>Eisai Ltd., Hatfield, UK</i>	
11.45 a.m	<b>OC34</b> - Comparing computerized versus conventional neuropsychological tests of memory: factors influencing sensitivity to donepezil <u>Judith Jaeger</u> (1,2,3), Adina Soaita (1), Joanne Gale (1), Kristin Hannesdottir (4) (1) <i>CogState, Inc. New Haven, CT, USA</i> , (2) <i>Albert Einstein Coll of Medicine, Bronx, NY,USA</i> , (3) <i>University of Manchester, UK</i> , (4) <i>AstraZeneca Research &amp; Development, Cambridge, MA, USA</i>	
12.00 p.m	<b>OC34bis</b> - The INSIGHT study: Conceptual considerations on the preclinical states of AD <u>Bruno Dubois</u> , MD, PhD (1), Harald Hampel, MD, PhD (2) (1) <i>Department of Neurology, Salpêtrière Hospital, Paris, France</i> , (2) <i>Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany</i>	

# CTAD 2013 Program

Friday, November 15<sup>th</sup>

## NEUROIMAGING PET FOR CLINICAL TRIALS - California Ballroom C

Moderators : Dorene Rentz, Stephen Salloway

10.45 a.m **OC35** - A multivariate FDG PET classifier metric improves prediction of cognitive change in Normals, MCI and AD patients

Lisa Mosconi, PhD (1,2,3), Randolph D Andrews, MS (1,2), Ana S Lukic, PhD (1,4), Miles N Wernick (1,4,5), Stephen C Strother (1,4,5), Enchi Liu (7), Richard Margolin (7), Mark E Schmidt (8), Dawn C Matthews (1,2), and the Alzheimer's Disease Neuroimaging Initiative

(1) ADM Diagnostics, Chicago, IL USA, (2) Abiant Inc., Grayslake, IL USA, (3) Department of Psychiatry, New York University School of Medicine, New York, NY, USA, (4) Predictek Inc., Chicago, IL USA, (5) Illinois Institute of Technology, Chicago, IL USA, (6) Rotman Research Institute, Baycrest, Toronto, ON, Canada, (7) Janssen Alzheimer Immunotherapy, South San Francisco, CA USA, (8) Janssen Research and Development, Beerse, Belgium

11.00 a.m **OC36** - Longitudinal morphometric characterization of mild cognitive impairment patients in WP5 Pharmacog/E-ADNI study: preliminary data

Martina Bocchetta, MS, on behalf of the PharmaCog Consortium

Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

11.15 a.m **OC37** - Validation of the EADC-ADNI harmonized protocol for manual hippocampal segmentation: preliminary results

Martina Bocchetta, MS for the EADC-ADNI group for the Harmonization of the Harmonized Protocol

IRCCS S.Giovanni di Dio-Fatebenefratelli, Brescia, Italy

11.30 a.m **OC38** - ETNA3, a clinical randomized study assessing 3 cognitive-oriented therapies in Alzheimer's disease

Hélène Amieva, PhD (1,2), Jean-François Dartigues, MD, PhD (1,2)

(1) INSERM U897 Epidemiology and Biostatistics Unit, Bordeaux, France, (2) CMRR Bordeaux-Pellegrin, France

11.45 a.m **OC39** - Novel cognitive outcomes for preclinical Alzheimer's disease prevention trials

Dorene M. Rentz, PsyD (1), Adrian Schembri, DPsych (2), David Salmon, PhD (4), Michael Donohue, PhD (4), Paul Maruff, PhD (2), Paul Aisen, MD (4), Reisa A. Sperling, MD (1)

(1) Departments of Neurology, Massachusetts General Hospital and Brigham and Women's Hospital, Boston, MA, (2) CogState Ltd, Melbourne, Australia, (3) University of California Irvine, Irvine, CA, (4) University of California at San Diego, San Diego, CA

12.00 p.m **OC40** - A dose-response relationship between computerized cognitive training and global cognition in older adults

Amit Lampit, Mag (FH) (1), Hariharan Hallock, MA (1), Rebecca Moss, MA (1), Sindy Kwok, PGDipPsych (1), Michael Rosser, BA, (2), Matthew Lukjanenko, PGDipPsych (1), Alana Kohn, PGDipPsych (1), Sharon Naismith, DPsych (Neuro) (3), Henry Brodaty, MBBS, DSc, FRANZCP (4), Michael Valenzuela, PhD, MBBS (Hons) (1)

(1) Regenerative Neuroscience Group, Brain and Mind Research Institute, University of Sydney, Sydney, Australia, (2) School of Psychology, University of New South Wales, Sydney, Australia, (3) Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, Sydney, Australia, (4) Dementia Collaborative Research Centre- Assessment and Better Care, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia

12.15 p.m **Lunch Break and poster sessions** - San Diego Ballroom

## 1.15 p.m - 3.15 p.m PARALLEL SESSIONS: ORAL COMMUNICATIONS

1.15 - 3.15 p.m

California Ballroom AB

**TREATMENT ASSESSMENT FOR CLINICAL TRIALS**

California Ballroom C

**BIOMARKERS FOR CLINICAL TRIALS**

## TREATMENT ASSESSMENT FOR CLINICAL TRIALS - California Ballroom AB

Moderators : Steve Ferris, Anton Porsteinson

1.15 p.m **OC41** - The API Colombia study: A prevention study in ADAD that will pave the way for prevention studies in sporadic AD

Paul R (1), Ayutyanont N (2), Hendrix S (3), Langbaum JB (2), Friesenhahn (1), Cho W (1), Ward M (1), Ho C (1), Tariot P (2), Reiman E (2), Lopera F (4)

(1) Genentech, South San Francisco, CA, USA, (2) Banner Alzheimer's Institute, Phoenix, AZ, USA, (3) Pentara Corporation, Salt Lake City, UT, USA, (4) Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia

## Friday, November 15<sup>th</sup>

### TREATMENT ASSESSMENT FOR CLINICAL TRIALS - California Ballroom AB

- 1.30 p.m **OC42** - A phase 2 study to investigate the effects of SAR110894 on cognition, daily function, apathy and sleep in mild to moderate Alzheimer's disease patients  
Jeanne Stemmelin (1), Stéphane Kirkesseli (1), Renata Martincova (1), Raphael Bejuit (1), Valérie Corp-dit-Genti (1), Gilmour Morrison (2), Blandine Nembo (1), Christine Fauveau (1), Hervé Bester (1), Agnès Menut (1), Sophie Claudel (1), John Alam (1)  
 (1) *Sanofi Research and Development, Chilly Mazarin, France*, (2) *Covance, Alnwick, UK*
- 1.45 p.m **OC43 - CANCELLED**
- 2.00 p.m **OC44** - A novel active immunization against C-terminal region of A $\beta$  enters clinical trial phase I  
Pedro Pesini, PhD, Manuel Sarasa, PhD  
*Araclon Biotech Ltd. Zaragoza. Spain*
- 2.15 p.m **OC45** - Anti-amyloid- $\beta$  therapy of Alzheimer disease (AD) patients by omega-3 supplementation: Recovery of innate immunity  
Milan Fiala, M.D (1), Verna Porter, M.D (2), Marc Dubourdeau, Ph.D (3)  
 (1) *Surgery Department, UCLA, Los Angeles, CA, USA*, (2) *Neurology Department, UCLA, Los Angeles, CA, USA*, (3) *Ambiotis SAS, Toulouse, France and Research Institute, University of Sydney, Sydney, Australia*
- 2.30 p.m **OC46** - Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study  
K. Wesnes (1), J.O. Rinne (2,3), J. Hänninen (4), M. Murphy (5), H. Riordan (5), J. Rouru (4), and the ALPO Study Group  
 (1) *Bracket Global, Goring-on-Thames, UK*, (2) *Turku PET Centre*, (3) *Turku University Central Hospital, Turku, Finland*, (4) *Orion Pharma, Turku, Finland*, (5) *World Wide Clinical Trials, King of Prussia, PA, USA*
- 2.45 p.m **OC47** - Intravenous Bapineuzumab in mild to moderate Alzheimer's disease: Results from two double-blind, placebo-controlled phase 3 trials  
Prisca Lucas, PharmD, PhD (1), David Li, PhD (2), Kasia Lobello, MD (2), Enchi Liu, PhD (3), H Robert Brashear, MD (3), Scot Styren, PhD (4), on behalf of the study 3133K1-3000/3001 Investigators  
 (1) *Pfizer PGRD, Paris, France*, (2) *Pfizer Inc, Collegeville, PA, USA*, (3) *Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA*, (4) *Pfizer, Inc, Groton, CT, USA*
- 3.00 p.m **OC48** - Relationship between cognitive and functional progression in patients with mild Alzheimer's disease  
Hong Liu-Seifert, PhD (1), Eric Siemers, MD (1), Karen Sundell, BS (1), Karen Price, PhD (1), Baoguang Han, PhD (1), Shannon Gardell, PhD (2)  
 (1) *Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA*, (2) *inVentiv Health Clinical, Somerset, NJ, USA*

### BIOMARKERS FOR CLINICAL TRIALS - California Ballroom C

Moderators : Cristina Sampaio, Scott Turner

- 1.15 p.m **OC49** - Detection of ligand bound to  $\beta$  Amyloid in the lenses of for Alzheimer's disease diagnosis  
Charles Kerbage, PhD (1), Carl H. Sadowsky, MD (2), Pierre N. Tariot, MD (3), Marc Agronin, MD (4), Gustavo Alva, MD (5), 1\*, Dennis Nilan (1), Anne Cameron, PhD (1), Gerald D. Cagle, PhD (1)  
 (1) *Cognoptix, Inc., Acton, MA, USA*, (2) *Premiere Research Institute and Nova Southeastern University, West Palm Beach, FL, USA*, (3) *Banner Alzheimer's Institute, Phoenix, AZ, USA*, (4) *Miami Jewish Health Systems, Miami, FL, USA*, (5) *ATP Clinical Research Inc. Costa Mesa, CA, USA*
- 1.30 p.m **OC50** - Prediction of cognitive and functional decline in patients with mild cognitive impairment by multiple brain volumes automatically extracted from structural MRI  
Robin Wolz, PhD (1,2), Peng Yu, PhD (3), Adam J.Schwarz, PhD (3), Kate McLeish, PhD (1), Daniel Rueckert, PhD (1,2), Derek Hill, PhD (1)  
 (1) *IXICO Ltd, London, UK*, (2) *Imperial College London, London, UK*, (3) *Elli Lilly and Company, Indianapolis IN, USA*

# CTAD 2013 Program

Friday, November 15<sup>th</sup>

## BIOMARKERS FOR CLINICAL TRIALS - California Ballroom C

- 1.45 p.m **OC51** - Resting-state functional MRI standardization for multi-center clinical trials  
David Scott, PhD (1), Ping-Chun Chiao, PhD (2), Jeff Sevigny, MD (2), Joyce Suhy, PhD (1)  
*(1) Synarc, Inc, Newark, CA, USA, (2) Biogen Idec, Inc Weston, MA, USA*
- 2.00 p.m **OC52** - Event related potentials: a cognitive biomarker for diagnosis of early-stage Alzheimer disease  
Marco Cecchi, PhD (1), Shauna Burkholder, MS (1), Sarah Berg, PhD (1), Carl Sadowsky, MD (2), Paul Solomon, PhD (3), P.Murali Doraiswamy, MBBS (4), Charles Smith, MD (5), Gregory Jicha, MD, PhD (5), Steven Arnold, MD (6), Bradley Folley, PhD (7), David Casey, MD (8), Andrew E. Budson, MD (9)  
*(1) Neuronetrix, KY, USA, (2) Premiere Research Institute, FL, USA, (3) The Memory Clinic, VT, USA, (4) Psychiatry Department, Duke University, NC, USA, (5) Neurology Department, University of Kentucky, KY, USA, (6) Psychiatry Department, University of Pennsylvania, PA, USA, (7) Norton Neuroscience, Norton Healthcare, KY, USA, (8) Psychiatry Department, University of Louisville, KY, USA, (9) Boston Center for Memory, MA, USA*
- 2.15 p.m **OC53** - In contrast to lower brain glucose uptake, brain ketone uptake is unchanged in mild Alzheimer's disease: A dual tracer PET study comparing 18F-FDG and 11C-acetoacetate  
Alexandre Castellano, PhD (1), Scott Nugent (1), Melanie Fortier (1), Nancy Paquet (2), Christian Bocti (1), Martin Lepage (3), Eric Turcotte (3), Tamas Fulop (1), Stephen Cunnane (1)  
*(1) Research Center on Aging, CASS-IUGS, (2) Clinical Research Center, (3) Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Sherbrooke, Québec, Canada*
- 2.30 p.m **OC54** - A panel of ten plasma lipids identifies antecedent memory impairment in older adults  
Massimo S. Fiandaca  
*Departments of Neurology and Neuroscience, Georgetown University Medical Center, Washington, DC, USA*
- 2.45 p.m **OC 55** - The A $\beta$  oligomer count in CSF is a biomarker for Alzheimer's disease  
Lei Wang-Dietrich, PhD (1), Susanne Aileen Funke, PhD (1), Eva Birkmann, PhD (1,2), Dieter Willbold, PhD (1,2)  
*(1) Research Centre Juelich, Juelich, Germany, (2) Heinrich-Heine-University, Duesseldorf, Germany*
- 3.00 p.m **OC56** - Reconstruction of entire chronological changes of multiple biomarkers in Alzheimer's disease from ADNI data by modeling: Significance of classification by Amyloid beta in CSF  
Akihiro Hisaka, PhD (1), Takaa kilshida, MS (2), Masashi Honma, MS (2), Kazutoshi Yokozuka, MS (3), Hidefumi Kasai, MS (3), Takashi Moritoyo, MD, PhD (4), Yoshihiro Arakawa, PhD (5), Takeshi Watsubo, MD, PhD (6), Hiroshi Suzuki, PhD (2)  
*(1) Pharmacology and Pharmacokinetics, The University of Tokyo Hospital, Tokyo, Japan, (2) Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan*
- 3.15 p.m **Coffee Break and poster sessions** - San Diego Ballroom



# CTAD 2013 Program



## Friday, November 15<sup>th</sup>

3.45 p.m	<p><b>KEYNOTE</b> - California Ballroom ABC Moderator : Jacques Touchon <b>Designing drug trials taking into account neuropsychiatric symptoms of AD</b> Jeffrey Cummings, MD- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV – USA</p>
4.15 p.m	<p><b>SYMPOSIUM 4</b> - California Ballroom ABC Internet screening of cognition as a method for recruiting to clinical trials in prodromal Alzheimer's disease Moderators: John Harrison, PhD, <i>Metis Cognition, Wiltshire, UK</i></p> <ol style="list-style-type: none"><li>1. Scientific foundation of internet based cognitive screening for recognition of prodromal Alzheimer's disease <u>Paul Maruff</u> PhD (1), Judy Jaeger, PhD (1), Yen Ying Lim, PhD (2), Ara Khachaturian, PhD (3) <i>(1) CogState Ltd, (2) Florey Institute of Neuroscience and Mental Health, Melbourne Australia, (3) PAD2020: The Campaign to Prevent Alzheimer's disease by 2020. Washington, DC. USA</i></li><li>2. Does internet screening of cognition deliver appropriate subjects for trials of prodromal AD? A perspective from industry <u>Bruce Alcala</u>, PhD (1), Michelle Gee, PhD (1) Andrew Satlin, MD (1) <i>(1) Eisai, Woodcliff Lake, NJ, USA</i></li><li>3. Can internet based cognitive screening deliver appropriate patients to clinical research units for trials in prodromal AD? <u>Larry Ereshefsky</u>, PharmD <i>PAREXEL International, and California Clinical Trials Medical Group, Glendale, CA, USA</i></li></ol>
5.30 p.m	<p><b>KEYNOTE</b> - California Ballroom ABC Moderator : Mathieu Ceccaldi <b>Ethical issues in AD prevention trials: genetics, biomarkers and treatment risk</b> Serge Gauthier, MD, <i>FRCPC, McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada</i></p>

# CTAD 2013 Program

## Saturday, November 16<sup>th</sup>

8.00 a.m

**KEYNOTE** - California Ballroom AB

Moderator : Paul Aisen

**Novel immunotherapy approaches**

David Holtzman, MD - Professor and Chairman of Neurology, Associate Director of the Alzheimer's Disease Research Center, Washington University in St. Louis, MO – USA

8.30 - 10.00 a.m

California Ballroom AB

8.30 - 9.45 a.m

**SYMPOSIUM 5**

Metabolic dysregulation in the Alzheimer brain: challenges and opportunities

**8.30 a.m - 10.00 a.m PARALLEL SESSIONS**

California Ballroom C

**ORAL COMMUNICATIONS**

8.30 - 9.00 a.m

**BIOMARKERS FOR CLINICAL TRIALS**

9.00 - 10.00 a.m

**PRECLINICAL STUDIES IN AD**

8.30 a.m

**SYMPOSIUM 5** - California Ballroom AB

Metabolic dysregulation in the Alzheimer brain: challenges and opportunities

Moderator : Samuel T Henderson, PhD,  
AcceraInc, Broomfield, CO, USA

1. Induced ketosis in mild to moderate Alzheimer's disease

Samuel T Henderson, PhD  
Accera Inc, Broomfield, CO, USA

2. Fuel-specific regional metabolic deterioration in the brain in the elderly and in early Alzheimer's disease

Stephen Cunnane, PhD1, Scott Nugent, MSc1, Alex Castellano, MSc1, Kewei Chen, PhD2, Eric Turcotte, MD, PhD1, TamasFulop, MD, PhD1, Eric Reiman, MD, PhD2

(1) Research Center on Aging and Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada

(2) Banner Alzheimer's Institute, Phoenix, AZ, USA

3. Dietary intervention to ameliorate neurocognitive decline with aging

Robert Krikorian, PhD

Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati Academic Health Center, Cincinnati, OH, USA

**BIOMARKERS FOR CLINICAL TRIALS** - California Ballroom C

Moderators : Robert Rissman, Reisa Sperling

8.30 a.m

**OC57** - Alzheimer's disease biomarkers as outcome measures for clinical trials in MCI

Annapaola Prestia, PsyD (1), Anna Caroli, PhD (1,2), Sara Wade, PhD (3,4), Kewei Chen, PhD (4), Napatkamon Ayutyanont, PhD (4), Susan M. Landau, PhD (5), Cindee M. Madison, MS (5), Cathleen Haense, MD (6), Karl Herholz, MD (7), Eric M. Reiman, MD (4), William J. Jagust, MD (5), Giovanni B. Frisoni, MD (1), Martina Bocchetta, MS

(1) Laboratory of Epidemiology and Neuroimaging -IRCCS S. Giovanni di Dio-FBF, Brescia, Italy, (2) Medical Imaging Unit, Biomedical Engineering Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy, (3) Department of Engineering, University of Cambridge, Cambridge, UK, (4) Department of Decision Science, Bocconi University, Milan, Italy, (5) Banner Alzheimer's Institute, Phoenix (AZ), USA, (6) Helen Wills Neuroscience Institute, University of California, Berkeley (CA), USA, (7) Hannover Medical School, Clinic for NuclearMedicine, Hannover, Germany, (8) University of Manchester, UK

8.45 a.m

**OC58** - Factors that influence use of plasma Amyloid beta as a biomarker of AD

Robert Rissman, Michael Donohue, Setareh Moghadam, Chung-Kai Sun, Steven Edland, Paul Aisen  
Department of Neurosciences, University of California San Diego, San Diego, CA, USA

## Saturday, November 16<sup>th</sup>

### PRECLINICAL STUDIES IN AD - California Ballroom C

Moderators : Ron Petersen, Jacques Touchon

- 9.00 a.m **OC59** - Dissecting the anatomy of computerised cognitive training: systematic review and meta-analysis of RCTs in older adults  
Amit Lampit, Mag(FH), Hariharan Hallock, MA, Michael Valenzuela, PhD, MBBS(Hons)  
Regenerative Neuroscience Group, Brain and Mind Research Institute, University of Sydney, Sydney, Australia
- 9.15 a.m **OC60** - A centrally active ACE inhibitor promotes signs of hippocampal neuroregeneration in the Tg2576 model of Alzheimer's disease  
Andreas Langer, PhD, Said AbdAlla, PhD, Xuebin Fu, MSc, Ursula Quitterer, PhD  
Molecular Pharmacology Unit, Swiss Federal Institute of Technology, Zurich, Switzerland
- 9.30 a.m **OC61** - The anti-amyloid chaperone BRICHOS efficiently prevents amyloid  $\beta$ -peptide CNS toxicity in *Drosophila melanogaster*  
Erik Hermansson, PhDstud (1), Bengt Winblad, MD, PhD (1), Jan Johansson, MD, PhD (1,2,3), Jenny Presto, PhD (1)  
(1) KI Alzheimer Disease Research Centre, Dept NVS, Karolinska Institutet, Stockholm, Sweden, (2) Department of Anatomy, Physiology and Biochemistry, Swedish University
- 9.45 a.m **OC62** - Presenilin/ $\gamma$ -secretase function to cleave pathological A $\beta$ 42/43  
Masayasu Okochi, MD, Shinji Tagami, MD, Kanta Yanagida, PhD, Yasuo Ihara, MD  
Osaka University, Osaka, Japan
- 10.00 a.m **Coffee Break and poster sessions** - San Diego Ballroom

10.30 a.m

### SYMPOSIUM 6 - California Ballroom AB

Clinical trials in early stage Alzheimer's disease: CSF biomarkers symposium

Moderator : Jacques Touchon, MD, PhD, *Montpellier University Hospital, Memory Center and INSERM U1061, Montpellier, France*

1. Brain amyloid-beta peptides dynamics in Alzheimer's disease

Randall Bateman, MD, PhD

*Washington University, School of Medicine, St Louis, Missouri, USA*

2. Neurochemical biomarkers in Alzheimer's disease and related disorders: novel detection methods of cerebrospinal fluid biomarkers are emerging

Christophe Hirtz, PhD

*INSERM U1040 and Institut de Recherche en Biothérapie, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France*

3. Relevance of cerebrospinal fluid Alzheimer's disease biomarkers in clinical practice

Audrey Gabelle, MD, PhD

*Department of Neurology, Memory Center, Montpellier University Hospital and INSERM U1040, France*



# POSTER PRESENTATIONS

## *Themes*

<b>THEME: CLINICAL TRIALS METHODOLOGY</b> .....	p. 19
P1 to P11	
<b>THEME: CLINICAL TRIALS RESULTS</b> .....	p. 20
P12 to P18	
<b>THEME: CLINICAL TRIALS: IMAGING</b> .....	p. 21
P19 to P31	
<b>THEME: CLINICAL TRIALS BIOMARKERS</b> .....	p. 23
P32 to P44	
<b>THEME: CLINICAL TRIALS: COGNITIVE ENDPOINTS</b> .....	p. 24
P45 to P47	
<b>THEME: CLINICAL TRIALS: COGNITIVE ASSESSMENTS</b> .....	p. 25
P48 to P54	
<b>THEME: HEALTH ECONOMICS AND CLINICAL TRIALS</b> .....	p. 25
P55 to P56	
<b>THEME: EPIDEMIOLOGY AND CLINICAL TRIALS</b> .....	p. 26
P57 to P58	
<b>THEME: ANIMAL MODELS AND CLINICAL TRIALS</b> .....	p. 26
P59 to P64	
<b>THEME: NEW THERAPIES AND CLINICAL TRIALS</b> .....	p. 27
P65 to P76	

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS METHODOLOGY

- P1** **THERAPEUTIC STRATEGIES TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS USING FLUORESCENT CONJUGATED POLYMER**  
Parameswar K. Iyer, PhD, B. Muthuraj, MSc, Atul K. Dwivedi, PhD, Sameer Hussain, MSc  
*Department of Chemistry, Indian Institute of Technology, Guwahati, Assam – INDIA*
- 
- P2** **CHOOSING ALZHEIMER'S DISEASE PREVENTION TRIAL POPULATIONS**  
Joshua D. Grill, PhD (1), Sarah Monsell (2)  
*(1) Mary Easton Center for Alzheimer's Disease Research, Department of Neurology, UCLA, Los Angeles, CA, (2) National Alzheimer's Coordinating Center, University of Washington, Seattle, WA*
- 
- P3** **DOES STUDY PARTNER TYPE IMPACT THE RATE OF ALZHEIMER'S DISEASE PROGRESSION?**  
Joshua D. Grill, PhD (1), Yan Zhou, PhD (1), Jason Karlawish, MD (3), David Elashoff, PhD (1,2)  
*(1) Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, (2) Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, (3) University of Pennsylvania, Perelman School of Medicine, Departments of Medicine, and Medical Ethics and Health Policy, Penn Memory Center, Philadelphia, PA*
- 
- P4** **SELECTING ACCEPTABLE CAREGIVER INFORMANTS FOR AD CLINICAL TRIALS : IS MORE CARE NEEDED ?**  
Priscilla Samuelson, RN and David S. Miller, MD, MA  
*Bracket, Wayne, PA, USA*
- 
- P5** **PREDICTORS OF PLACEBO RESPONSE IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE: FINDINGS FROM 12-WEEK, PHASE 2A CLINICAL TRIALS**  
Teresa Buracchio, MD, Andreas Meier, MD, Ferenc Martenyi, MD, Qi Tang, PhD, Laura Gault, MD, PhD  
*AbbVie Inc. North Chicago, IL, USA*
- 
- P6** **SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXHIBIT EVIDENCE OF PRACTICE EFFECTS ON REPEATED MEASURES OF THE ALZHEIMER'S DISEASE ASSESSMENT SCALE-COGNITIVE SUBSCALE AND THE MINI-MENTAL STATUS EXAMINATION**  
Andreas Meier, MD, Teresa Buracchio, MD, Ferenc Martenyi, MD, Qi Tang, PhD, Laura Gault, MD, PhD  
*AbbVie Inc., North Chicago, IL, USA*
- 
- P7** **PRACTICAL EXPERIENCE OF CONSENSUS DETERMINATION IN A GLOBAL, PHASE 2 ALZHEIMER'S DISEASE CLINICAL TRIAL (CN156-018)**  
Matthew Gabel, PhD (1), Vladimir Coric, MD (2), Robert Berman, MD (2), Jesse Cedarbaum, MD (2), Howard Chertkow, MD (3), Rajan Duara, MD (4), Stephen Kaplita, PhD (2), Christine Moore, PhD (5), Norman Foster, MD (6)  
*(1) Department of Political Science, Washington University, St. Louis, MO, USA, (2) Neuroscience Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT USA (3) Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, PQ CA, (4) Department of Neurology, McGill University School of Medicine, Montreal, Quebec CA, (5) Wien Center for Alzheimer's Disease and Memory Disorders, Mt. Sinai Medical Center, Miami Beach, FL USA, (6) InVentiv Health Clinical, Cary, NC USA, (7) Center for Alzheimer's Care, Imaging, and Research and Department of Neurology, University of Utah, Salt Lake City, UT USA*
- 
- P8** **OPTIMIZING THE ANALYSIS OF PHASE 2 AND PHASE 3 CLINICAL TRIALS IN ALZHEIMER'S DISEASE**  
Stephanie Stanworth, MS, Noel Ellison, MS, Leah Garriott, MS, Suzanne Hendrix, PhD  
*Pentara Corporation, Salt Lake City, UT – USA*
- 
- P9** **ADCS ELECTRONIC DATA CAPTURE (EDC) - SMART ELECTRONIC CASE REPORT FORM (ECRF) FRAMEWORK**  
Gustavo A. Jimenez-Maggiore, MBA, Ronald G. Thomas, PhD, Jia-shing So, BS, Stefania Bruschi, MS, Hongmei Qiu, BS, Phuoc Hong, BA, Paul S. Aisen, MD  
*Neurosciences department, University of California at San Diego, La Jolla, CA, USA*
- 
- P10** **DOSE SELECTION FOR ELND005 (SCYLLO-INOSITOL) IN NEUROPSYCHIATRIC CLINICAL TRIALS: USE OF MODELING AND SIMULATIONS (M&S) OF POPULATION PHARMACOKINETIC MODEL TO ESTIMATE TARGET DRUG EXPOSURES**  
Earvin Liang, PhD (1), Michelle Green, PhD (2), Matthias Kurth, MD, PhD (1), J Patrick Kesslak, PhD (1), Susan Abushakra, MD (1)  
*(1) Elan Pharmaceuticals, Inc., San Mateo, CA, USA, (2) Pharsight, a Cartara Corporation, Sunnyvale, CA, USA*
-

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS METHODOLOGY

- P11** **RETROSPECTIVE REVIEW OF SAFETY AND TOLERABILITY OF CONTINUOUS CEREBROSPINAL FLUID (CSF) COLLECTIONS DURING PHASE 1 PHARMACOKINETIC/PHARMACODYNAMIC STUDIES IN HEALTHY VOLUNTEERS AND PATIENTS**  
Hakop Gevorkyan (1), Brett A. English (1,3), David Han (1), Lev Gertsik (1), Melody Avakian (2), Jasmine Pauly (2), Stanford S. Jhee (2), Larry Ereshefsky (2,4)  
(1) California Clinical Trials Medical Group, (2) PAREXEL International, (3) Glendale, CA, Dept. of Pharmacology, (4) Vanderbilt University Medical Center, Nashville, TN., Glendale, CA, (4) University of Texas College of Pharmacy, Austin, TX

## THEME: CLINICAL TRIALS RESULTS

- P12** **SENSITIVITY TO CHANGE OF VALIDATED ALZHEIMER'S DISEASE INSTRUMENTS IN AN ASIAN SAMPLE**  
Joan Shen MD PhD (1), Qi Shen MD PhD (1), Jin-Shei Lai PhD (2), Jennifer Beaumont (2), Holly Yu (1), Zhenxin Zhang MD (3), Huali Wang MD PhD (4), Seongyoon Kim MD (5), Timothy Kwok MD (6), Christopher Chen MD (7), Shuu-Jiun Wang MD (8), Dongyoung Lee MD (9), John Harrison PhD (10), Jeffrey Cummings MD\* (11)  
(1) Pfizer Inc. USA, (2) Feinberg School of Medicine at Northwestern University, USA, (3) Peking Union Medical College Hospital, China, (4) The Sixth Hospital of Peking University, China, (5) Asan Medical Center, South Korea, (6) Prince of Wales Hospital, Hong Kong, China, (7) National University Hospital, South Korea, (8) Taipei Veterans General Hospital, Taiwan, (9) Seoul National Univeristy Hospital. South Korea, (10) Metis Cognition Ltd. Dept. of Medicine, Imperial College, London, UK, (11) Cleveland Clinic Lou Ruvo Center for Brain Health, USA
- P13** **UNDIAGNOSED PRE-DIABETES OR DIABETES IS HIGHLY PREVALENT IN INDIVIDUALS WITH MILD-MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE**  
R.S.Turner (1), S.Craft (2), P. Aisen (3)  
(1) Georgetown University, Washington, D.C., (2) Wake Forest University, Winston-Salem, N.C., (3) University of California, San Diego, Ca, U.S.A
- P14** **HIGH VARIABILITY AND LACK OF CHANGE ON THE ADAS-COG: PLACEBO ANALYSES OF THE CODR DATABASE**  
Danielle Popp, PhD (1), Lori M. Garzio, MS (1), Peter Boehm, MS (1), Christopher Randolph, PhD (1,2)  
(1) MedAvante, Inc., (2) Department of Neurology, Loyola University Medical Center
- P15** **AZD3293 A NOVEL BACE1 INHIBITOR : EFFECT ON PLASMA AND CSF AB PEPTIDES FOLLOWING SINGLE AND MULTIPLE-DOSE ADMINISTRATION**  
Samantha Budd Haeberlein, PhD (1), Robert Alexander, MD (1), Alan Kugler, PhD (1), Gvido Cebers MD, PhD (1), Naidong Ye, PhD (1), Tina Olsson, PhD (1), Doug Burdette, PhD (1), David Han, MD (2), Ronald Goldwater, MD (2), Larry Ereshefsky PharmD, FCCP (2)  
(1) AstraZeneca, Cambridge, MA, USA, (2) Parexel International Early Phase, Glendale, CA, USA
- P16** **EFFECT OF MEMANTINE ON THE PROGRESSION OF DRIVING IMPAIRMENT IN PATIENTS WITH MILD ALZHEIMER'S DISEASE**  
Peter J. Holland, MD, DFAPA, FACOEM (1), Ruth M. Tappen, EdD, RN, FAAN (2), Lori Fisher, MA (3), Anna Lisa Curtis, BA (4), Jeff Apter, MD (5)  
(1) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (2) Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton, FL, USA, (3) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (4) Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA, (5) Global Clinical Trials LLC, Princeton, NJ, USA
- P17** **CHINESE HERBAL MEDICINE IN VASCULAR DEMENTIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**  
Jing Shi, MD, WenjiaJian MD, Jingnian Ni, MD, Xuekai Zhang PhD, Mingqing Wei, MD  
Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine
- P18** **AMYLOID PET SCREENING RESULTS BY APOE E4 STATUS FROM A PHASE 1B CLINICAL STUDY 221AD103 IN PRODROMAL TO MILD AD PATIENTS**  
Ping Chiao, PhD (1), Joyce Suhay, PhD (2), Jerry Barakos, MD (2), Meredith Burke, PhD (2), Greg Klein, PhD (2), Ajay Verma, MD, PhD (1), Jeff Sevigny, MD (1)  
(1) Biogen Idec, Inc Weston, MA, USA, (2) Synarc, Inc, Newark, CA, USA

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS: IMAGING

### **P19 USEFULNESS OF DTI (DIFFUSION TENSOR IMAGE) AS AN EARLY DIAGNOSTIC TOOL FOR SUBJECTIVE MEMORY IMPAIRMENT AND MILD COGNITIVE IMPAIRMENT**

Kawon Jung, MD, Dong Won Yang, MD

Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea

### **P20 HIPPOCAMPAL VOLUME CHANGE MEASUREMENT: EXPERT MANUAL OUTLINING IS AS REPRODUCIBLE AS THE AUTOMATED METHODS FREESURFER AND FIRST**

Philip Scheltens (1,6), Emma R. Mulder (1,2), Remko A de Jong (1,2), Dirk L Knol (3), Ronald A van Schijndel (1,4), Keith S Cover (5), Pieter J Visser (6), Frederik Barkhof (1,2), Hugo Vrenken (2,5) for ADNI7

(1) Image Analysis Center, VU University Medical Center, Amsterdam, The Netherlands, (2) Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands, (3) Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands, (4) Department of Information & Communication Technology, VU University Medical Center, Amsterdam, The Netherlands, (5) Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands, (6) Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands, (7) Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu)

### **P21 ITALIAN NETWORK FOR AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION**

Giovanni B. Frisoni, MD (1), Claudio Babiloni, PhD (2), Amalia C. Bruni, MD (3), Elio Scarpini, MD (4), Sandro Sorbi, MD (5), Fabrizio Tagliavini, MD (6), [Martina Bocchetta, MS](#) (1), Michela Pievani, PhD (1), Alessandro Padovani, MD, PhD (7)

(1) LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine) IRCCS – S. Giovanni di Dio – Fatebenefratelli Brescia, Italy, (2) Università di Roma “La Sapienza”, Roma, Italy, (3) Centro Regionale di Neurogenetica, Lamezia Terme, Italy, (4) IRCCS Ospedale Policlinico, Milano, Italy, (5) Università di Firenze, Firenze, Italy, (6) IRCCS Fondazione Istituto Neurologico Carlo Besta, Milano, Italy, (7) Università di Brescia, Brescia, Italy

### **P22 PROVIDING STANDARDIZED LABELS OF THE EADC-ADNI HARMONIZED HIPPOCAMPAL PROTOCOL FOR AUTOMATED ALGORITHM TRAINING**

Boccardi M, PhD (1), [Bocchetta M, MS](#) (1), Nishikawa M, MD (2), Ganzola R, MS (3), Grothe M, PhD (4), Wolf D, MS (5), Duchesne S, PhD (3), Jack CR Jr, MD (6), Frisoni GB, MD (1)

(1) IRCCS S. Giovanni di Dio-Fatebenefratelli, Brescia, Italy, (2) Kawamura Gakuen Woman's University, Abiko, Japan, (3) Université Laval and Centre de Recherche Université Laval – Robert Giffard, Quebec City, Canada, (4) German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany, (5) University Medical Center Mainz, Mainz, Germany, (6) Mayo Clinic, Rochester, NY, USA

### **P23 A MAGNETIC RESONANCE SPECTROSCOPY STUDY TO EXPLORE THE EFFECTS OF THE MEDICAL FOOD SOUVENAIID ON BRAIN METABOLITES IN MILD ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE DATA**

Anne Rijpma, MSc (1,2), Olga Meulenbroek, PhD (1,2), Marinette van der Graaf, PhD (3,4), [Marieke Lansbergen](#), PhD (5), Anke Bongers, MSc (5), Arend Heerschap, PhD (3), Marcel Olde Rikkert, MD, PhD (1,2)

(1) Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (2) Alzheimer Centre Nijmegen, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (3) Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (4) Department of Paediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands

### **P24 PREDICTIVE VALUE OF BASELINE HIPPOCAMPAL VOLUMES AND BRAIN AMYLOID BURDEN ON ATROPHY RATES FOR PREDEMENTIA ALZHEIMER'S DISEASE SUBJECTS WITH DATA FROM STUDY CN156-018 AND ADNI-1**

[Luc Bracoud](#), MSc (1), Kenneth Marek, MD (2), Jesse Cedarbaum, MD (3), Joël Schaefer, PhD (1), Susan Mendick, MPH (2), Robert Berman, MD (3), Florent Roche, MSc (1), Feng Luo, PhD (3), Wendy Hayes, DO (3), Stephen Kaplita, MSc (3), John Seibyl, MD (2), Chahin Pachai, PhD (1), Vlad Coric, MD (3) and the Alzheimer's Disease Neuroimaging Initiative

(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Molecular Neuroimaging, New Haven, CT, USA, (3) Bristol Myers Squibb, Princeton, NJ, USA

### **P25 COMPARISON OF INTRACRANIAL VOLUME QUANTIFICATION BASED ON 2D T2\* AND 3D T1-WEIGHTED MRI SEQUENCES**

[Joël Schaefer](#), PhD (1), Feng Luo, PhD (2), Sylvain Gouttard, MSc (1), Jesse Cedarbaum, MD (2), Luc Bracoud, MSc (1), Vlad Coric, MD (2), Florent Roche, MSc (1), Stephen Kaplita, MSc (2), Audrey Istace, MSc (1), Wendy Hayes, DO (2), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Robert Berman, MD (2)

(1) BioClinica, Lyon, France and Newtown, PA, USA, (2) Bristol Myers Squibb, Princeton, NJ, USA

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS: IMAGING

- P26** **COMPARISON OF BOUNDARY SHIFT INTEGRAL AND TENSOR BASED MORPHOMETRY TO ASSESS VOLUME CHANGES ON WHOLE BRAIN AND LATERAL VENTRICLES – APPLICATION TO STUDY CN156-018**  
Audrey Istace, MSc (1), Vlad Coric, MD (2), Florent Roche, MSc (1), Stephen Kaplita, MSc (2), Joël Schaerer, PhD (1), Feng Luo, MD (2), Sylvain Gouttard, MSc (1), Jesse Cedarbaum, MD (2), Luc Bracoud, MSc (1), Wendy Hayes, DO (2), Boubakeur Belaroussi, PhD (1), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Robert Berman, MD (2)  
(1) *BioClinica, Lyon, France and Newtown, PA, USA*, (2) *Bristol Myers Squibb, Princeton, NJ, USA*
- 
- P27** **LONGITUDINAL VOLUMETRIC CHANGES IN STUDY CN156-018, AS COMPARED TO ADNI-1**  
Luc Bracoud, MSc (1), Robert Berman, MD (2), Florent Roche, MSc (1), Vlad Coric, MD (2), Sylvain Gouttard, MSc (1), Feng Luo, PhD (2), Joël Schaerer, PhD (1), Wendy Hayes, DO (2), Audrey Istace, MSc (1), Stephen Kaplita, MSc (2), Boubakeur Belaroussi, PhD (1), Hui-Jing Yu, PhD (1), Chahin Pachai, PhD (1), Jesse Cedarbaum, MD (2) and the Alzheimer's Disease Neuroimaging Initiative  
(1) *BioClinica, Lyon, France and Newtown, PA, USA*, (2) *Bristol Myers Squibb, Princeton, NJ, USA*
- 
- P28** **THE IMPACT OF THE WHITE MATTER HYPERINTENSITIES TO THE COGNITIVE FUNCTION IN THE PATIENTS WITH BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA**  
Bon D. Ku (1), Key Hyung Park (2), Hyun Jung Han (1), Young Chul Youn (3), Bora Youn (4), Kyung Won Park (5), Jae-Hong Lee (6), Eun-Joo Kim (7), Duk L. Na (8), Key Chung Park (9)  
(1) *Department of Neurology, Myongji Hospital, Kwandong University College of Medicine, Gyeonggi, Korea*, (2) *Department of Neurology, Gachon University Gil Hospital, Incheon, Korea*, (3) *Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea*, (4) *Department of Neurology, Kyung Yang University Hospital, Kyung Yang University College of Medicine, Daejeon, Korea*, (5) *Department of Neurology, Dong A University Medical Center, Dong A University College of Medicine, Busan, Korea\**, (6) *Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*, (7) *Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea*, (8) *Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine*, (9) *Department of Neurology, KyungHee University School of Medicine, Seoul, Korea, Seoul, Korea*
- 
- P29** **PROPOSITION OF T1-AXIAL VISUAL RATING SCALE FOR MEDIAL TEMPORAL ATROPHY FOR CLINICAL TRIALS OF ALZHEIMER'S DISEASE**  
Geon Ha Kim, MD (1), Jong Won Kim, MD (2), Kyoung-Gyu Choi, MD, PhD (1), Jong-Min Lee, PhD (3), Duk L. Na, MD, PhD (4), Jee-Hyang Jeong, MD, PhD (1)  
(1) *Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Republic of Korea*, (2) *Department of Emergency Medicine, Konkuk University Medical Center, Seoul, Republic of Korea*, (3) *Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea*, (4) *Department of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea*
- 
- P30** **AMYLOID PET SCREENING FOR ENROLLMENT INTO AD CLINICAL TRIALS: AN EFFECTIVE ENRICHMENT STRATEGY IN A PHASE 1B CLINICAL TRIAL**  
Jerome Barakos (1,2), Derk Purcell (1,2,3), Gregory Klein (1), Joyce Suhy (1), Joonmi Oh (1), Ping Chiao (4), Jeff Sevigny (4)  
(1) *Synarc Inc, Newark, CA, USA*, (2) *California Pacific Medical Center, San Francisco, CA, USA*, (3) *UC San Francisco, San Francisco, CA, USA*, (4) *Biogen Idec, Cambridge, MA, USA*
- 
- P31** **AMYLOID AND APOE4 INTERACT TO INFLUENCE COGNITIVE DECLINE OVER A SHORT FOLLOW UP PERIOD IN AGING**  
Elizabeth C. Mormino, PhD (1), Rebecca A. Betensky, PhD (2), Trey Hedden, PhD (3,4), Aaron P. Schultz, PhD (1,3,5), Andrew Ward, BA (5,6), Willem Huijbers, PhD (6), Dorene M. Rentz, PsyD (1,6), Keith A. Johnson, MD (1,3,6,7), Reisa A. Sperling, MD (1,3,6); the Alzheimer's Disease Neuroimaging Initiative\*; the Australian Imaging Biomarkers and Lifestyle flagship study of ageing\*\*; and the Harvard Aging Brain Study\*\*\*  
(1) *Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114*, (2) *Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115*, (3) *Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114*, (4) *Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, Massachusetts 02129*, (5) *Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114*, (6) *Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, MA, USA*, (7) *Division of Nuclear Medicine and Molecular Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA*



# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS BIOMARKERS

- P32** **MINIMALLY-INVASIVE DETECTION OF ALZHEIMER DISEASE USING 12 MICRORNAS**  
Cord Stähler (1), Petra Leidinger (2), Christina Backes (2), Karen Frese (3), Jan Haas (3), Klemens Ruprecht (4), Benjamin Meder (3), Eckart Meese (2), Andreas Keller (5)  
(1) Siemens Healthcare, Strategy, Erlangen, Germany, (2) Department of Human Genetics, Saarland University, Homburg, Germany, (3) Internal Medicine II, Heidelberg University, Heidelberg, Germany, (4) Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine Berlin, Berlin, Germany, (5) Chair for Clinical Bioinformatics, Saarland University, University Hospital, Saarbrücken, Germany
- 
- P33** **TIBET-MEDICINE (RATANASAMPIL INVOLVED IN PRODUCTION AND METABOLISM OF BETA-AMYLOID IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE AT HIGH ALTITUDE**  
ZHU Ai-qin, ZHONG Xing, LI Gou-feng, Li Ying-lan, Liao Bao-xia, Peng Hai, CHU Yi-de  
Institute of Geriatrics, Qinghai Provincial Hospital, Xining, China
- 
- P34** **HYPOCRETIN AND B-AMYLOID PEPTIDE INTERACTIONS IN ALZHEIMER'S DISEASE AND NARCOLEPSY**  
Yves DAUVILLIERS MD, PhD (1,2,3), Sylvain LEHMANN MD, PhD (4), Isabelle JAUSSENT PhD (1,2), Jacques TOUCHON, MD (2,3), Audrey GABELLE MD, PhD (3,4)  
(1) Sleep Unit, National Reference Network for Orphan Diseases (Narcolepsy, Hypersomnia, Kleine-Levin Syndrome), Department of Neurology, Gui de Chauliac Hospital, CHU Montpellier, France, (2) INSERM, U1061, Montpellier, Montpellier 1 University, France, (3) Clinical Research Memory Center Languedoc-Roussillon, Gui de Chauliac Hospital, CHU de Montpellier, France, (4) Biochimie-Protéomique Clinique – IRB – CCBHM -Inserm U1040 CHU Montpellier ; France
- 
- P35** **PLASMA B-AMYLOID 40 LEVELS ARE POSITIVELY ASSOCIATED WITH MORTALITY RISKS IN ELDERLY POPULATIONS: A POPULATION-BASED PROSPECTIVE STUDY**  
Audrey Gabelle, Susanna Schraen, Laure-Anne Gutierrez, Cecile Pays, Olivier Rouaud, Luc Buée, Jacques Touchon, Catherine Helmer, Jean-Charles Lambert, Claudine Berr  
From the Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU Gui de Chauliac Hospital, Department of Neurology, Montpellier, France (A.G, C.P, C.B, J.T.), INSERM U1061, Hôpital La Colombière, Montpellier, France (L.A.G., C.P, J.T, C.B.) and University Montpellier 1, Montpellier, France (A.G, J.T) ; From INSERM U744, Lille, France, and Institut Pasteur de Lille, Lille, France and Université de Lille Nord de France, Lille, France, and CHRU de Lille, Lille, France and INSERM U837, Lille, France (S.S, L.B, J.C.L); From INSERM 897; ISPED, Victor Segalen University, Bordeaux, France (C.H); From Centre Mémoire Ressources Recherche, CHRU Dijon, Department of Neurology, Dijon, France (O.R)
- 
- P36** **IMPACT OF THE FRENCH “NATIONAL PLAN FOR ALZHEIMER 2008-2012” ON THE USE OF CSF BIOMARKERS: THE PLM STUDY**  
Audrey Gabelle (1,2), Julien Dumurgier (3), Olivier Vercruysse (4), Claire Paquet (3,5), Stéphanie Bombois (4), Jean-Louis Laplanche (6), Katell Peoc'h (6), Susanna Schraen (7), Luc Buée (7), Florence Pasquier (4), Jacques Hugon (3,5), Jacques Touchon (1,8), Sylvain Lehmann (2)  
(1) Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université Montpellier I ; Montpellier, France, (2) Biochimie-Protéomique Clinique – IRB – CCBHM -Inserm U1040 CHU de Montpellier ; Montpellier, France, (3) Centre Mémoire Ressources Recherche Paris Nord Ile-de-France, hôpital Saint Louis -Lariboisière - Fernand Widal Hospital, APHP, Université Paris 7-Denis Diderot; Paris, France, (4) Centre Mémoire Ressources Recherche Lille, CHU de Lille, EA 1046, Université Lille-Nord de France; Lille, France, (5) Institut du Fer à Moulin, INSERM U839 ; Paris, France, (6) Laboratoire de Biochimie et Biologie Moléculaire, Hôpital Lariboisière, APHP-Inserm U705/UMR8206; Paris, France, (7) CHU de Lille, Centre de Biologie Pathologie; Université Lille-Nord de France; INSERM U837; Lille, France, (8) INSERM U1061, Hôpital la Colombière, CHU de Montpellier ; Montpellier, France
- 
- P37** **IMMUNIZATION AGAINST AB40 INDUCES AN INCREASE OF AB40 PLASMA LEVELS WHEREAS LEVELS OF AB42 REMAINED UNCHANGED**  
María Izco, Ana M<sup>a</sup> Lacosta, María Montañés, Virginia Pérez-Grijalba, Pedro Pesini, Manuel Sarasa  
Araclon Biotech Ltd. Zaragoza, Spain
- 
- P38** **THE EFFECTS OF AZD1446 (A NEURONAL NICOTINIC RECEPTOR AGONIST) ON QUANTIFIED ELECTROENCEPHALOGRAPHY (QEEG) IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE. QUANTITATIVE MEASUREMENTS USING A QEEG CHOLINERGIC INDEX**  
Kristinn Johnsen, PhD (1), Niclas Brynne, PhD (1,2), Peter Annas, PhD (2), Kristin Hannesdottir, PhD (3), Robert Alexander, MD, PhD (3), Märta Segerdahl, MD, PhD (2,4)  
(1) Department of Clinical R&D, MentisCuraehf., Reykjavik, Iceland, (2) Department of Clinical Neuroscience, AstraZeneca R&D, Södertälje, Sweden, (3) Neuroscience iMed, AstraZeneca R&D, Cambridge, MA – USA, (4) Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS BIOMARKERS

**P39** **PHARMACOLOGICAL REVERSAL OF AZD1446 AND DONEPEZIL AFTER SCOPOLAMINE INJECTIONS TO HEALTHY VOLUNTEERS. QUANTITATIVE MEASUREMENTS USING A QEEG CHOLINERGIC INDEX**  
Kristinn Johnsen, PhD (1), Niclas Brynne, PhD (1,2), Peter Annas, PhD (2), Kristin Hannesdottir, PhD (2), Robert Alexander, MD, PhD (2), Märta Segerdahl, MD, PhD (2,4)  
(1) Department of Clinical R&D, MentisCura ehf., Reykjavík, Iceland, (2) Department of Clinical Neuroscience, AstraZeneca R&D, Södertälje, Sweden, (3) Neuroscience iMed, AstraZeneca R&D, Cambridge, MA, (4) Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

**P40** **EXPERIMENTAL DESIGN, CALIBRATION, AND STATISTICAL ANALYSIS OF BLOOD PLASMA BIOASSAYS**  
Michael C Donohue, PhD (1,2), Robert A Rissman PhD (2,3), Chung-Kai Sun MS (2), Steve D Edland, PhD (1,3), Paul S Aisen, MD (2,3)  
(1) Division of Biostatistics & Bioinformatics, Department of Family & Preventive Medicine, (2) Alzheimer's Disease Cooperative Study, (3) Department of Neurosciences - University of California San Diego

**P41** **OLFACTORY IDENTIFICATION DEFICITS PREDICT RESPONSE TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT**  
P. Devanand, M.D. (1), Gregory H. Pelton, M.D.(1), Howard Andrews, Ph.D. (1), Bruce Levin, Ph.D. (2)  
(1) Department of Psychiatry, Columbia University, (2) Department of Biostatistics, Mailman School of Public Health, Columbia University

**P42** **A NOVEL GLYCAN BIOMARKER IN ALZHEIMER DISEASE**  
Sophia Schedin-Weiss, PhD (1), Qiushi Chen, PhD (2), Stuart Haslam, PhD (2), Anne Dell (2), Bengt Winblad, MD, PhD (1), Lars Tjernberg, PhD (1)  
(1) KI-Alzheimer Disease Research Center (KI-ADRC), Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Stockholm, Sweden, (2) Department of Life Sciences, Imperial College, London

**P43** **PLASMA BIOMARKERS ASSOCIATED WITH THE APOLIPOPROTEIN E (APOE) GENOTYPE AND AMYLOID-BETA IMAGING**  
Sophie Sokolow, PhD (1,2), Kristy S Hwang, BS (3,4), Edmond Teng, MD, PhD (3,5), Andreas Lazaris (6), Paul M. Thompson, PhD (3,4,7), Clifford R.Jack, Jr., MD (8), Leslie M. Shaw, PhD (9), John Q. Trojanowski, MD, PhD (10), Holly D. Soares, PhD (11), Michael W. Weiner, MD (12,13), Liana G. Apostolova MD (3,4)  
(1) School of Nursing, University of California at Los Angeles, CA, USA, (2) Brain Research Institute, University of California at Los Angeles, CA, USA, (3) Department of Neurology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA, (4) Imaging Genetics Center, Laboratory of Neuro Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA, (5) Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA, (6) Helen Wills Neuroscience Institute, University of California at Berkeley, Berkeley, CA, USA, (7) Department of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California at Los Angeles, CA, USA, (8) Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN, USA, (9) Department of Cancer Biology, Medical school of University of Massachusetts, Worcester, MA, USA, (10) Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA, (11) Bristol-Meyers Squibb, Wallingford CT, USA, (12) Departments of Medicine, Radiology, and Psychiatry, University of California at San Francisco, San Francisco, CA, USA, (13) Veterans Affairs Medical Center, San Francisco, CA

**P44** **NEW MODELING METHOD FOR ESTIMATION OF ENTIRE CHRONOLOGICAL CHANGES OF MULTIPLE BIOMARKERS FROM FRAGMENTED INFORMATION**  
Takaaki Ishida, MS (1), Akihiro Hisaka, PhD (2), Masashi Honma, MS (1), Kazutoshi Yokozuka, MS (3), Hidefumi Kasai, MS (3), Takashi Moritoyo, MD, PhD (4), Yoshihiro Arakawa, PhD (5), Takeshi Iwatsubo, MD, PhD (6), Hiroshi Suzuki, PhD (1)  
(1) Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, (2) Pharmacology and Pharmacokinetics, The University of Tokyo Hospital, Tokyo, Japan, (3) Bell Medical Solutions Inc. Tokyo, Japan, (4) Unit for Early and Exploratory Clinical Department, The University of Tokyo Hospital, Tokyo, Japan, (5) Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan, (6) Neuroscience, Faculty of Medicine, The University of Tokyo, Tokyo, Japan

## THEME: CLINICAL TRIALS: COGNITIVE ENDPOINTS

**P45** **ANALYSIS OF LEXIS IN SPONTANEOUS CONVERSATION WITH ALZHEIMER'S DISEASE PATIENTS**  
Renné Alegria, PhD (1,2), Cleide Rosana Prisco (3), Cassio MC Bottino (2), MD, PhD, Maria Inês Nogueira, PhD  
(1) Neuroscience and Behavior, Institute of Psychology, University of São Paulo, SP, Brazil, (2) PROTER- Old Age Research Group, Institute of Psychiatry, School of Medicine, University of Sao Paulo, SP, Brazil, (3) Institute of Biomedical Sciences, University of São Paulo, SP, Brazil

**P46** **CREATING A COMPOSITE SCORE : METHODOLOGY COMPARISON**  
Noel Ellison, MS, Suzanne Hendrix, PhD, Stephanie Stanworth, MS, Leah Garriott, MS  
Pentara Corporation, Salt Lake City, UT - USA

# POSTER PRESENTATIONS

## THEME: CLINICAL TRIALS: COGNITIVE ENDPOINTS

- P47** **LONG-TERM NEUROPSYCHIATRIC SYMPTOM INTENSITY IN ALZHEIMER'S DISEASE IS PREDICTABLE VIA SHORT-TERM SYMPTOM SEVERITY AS MEASURED BY SYMPTOMGUIDE™ SCORE**  
Kenneth Rockwood, MD, PhD (1,2), [Arnold Mitnitski](#), PhD (1,2), Matthew Richard, BSc (1), Matthias Kurth, MD, PhD (3), J Patrick Kesslak, PhD (3), Susan Abushakra, MD (3)  
(1) *DGI Clinical Inc., Halifax, NS, Canada*, (2) *Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada*, (3) *Elan Pharmaceuticals, San Francisco, CA USA*

## THEME: CLINICAL TRIALS: COGNITIVE ASSESSMENTS

- P48** **MODELING OF ADAS-COG PLACEBO RESPONSE IN ASIAN AND CAUCASIAN PATIENTS WITH ALZHEIMER'S DISEASE**  
An Hye Kim, MD (1), Kyoungsoo Lim, MD, PhD (1), Jae Yong Chung, MD, PhD (2)  
(1) *Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seongnam, Korea*, (2) *Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Korea*

- P49** **LONG-TERM EFFECT OF CURRENT ALZHEIMER'S MEDICATIONS ON COGNITIVE FUNCTION AMONG CHINESE ALZHEIMER'S DISEASE PATIENTS: A THREE YEAR PROSPECTIVE STUDY**  
[Chu LW](#) (1), Kwan F (1), Yik PY (1), Song YQ (2)  
(1) *Division of Geriatric Medicine, Department of Medicine, Queen Mary Hospital, The University of Hong Kong*, (2) *Department of Biochemistry, The University of Hong Kong*

- P50** **EFFICIENT SCREENING FOR MILD COGNITIVE IMPAIRMENT DUE TO AD FOR CLINICAL TRIAL ENROLLMENT**  
[Stephen W. Hurt](#), PhD (1), Bruce Albala, PhD (2), Paul Maruff, PhD (3)  
(1) *Psychiatry Department, Weill Cornell Medical College, White Plains, New York USA*, (2) *Eisai Inc., Woodcliff Lake, New Jersey, USA*, (3) *CogState, New Haven, Connecticut, USA*

- P51** **THE GOTHENBURG MCI STUDY: THE NEUROPSYCHOLOGICAL PROFILES OF INCIPIENT AD AND VASCULAR COGNITIVE DISORDER DIFFER**  
[Arto Nordlund](#), PhD, Maria Bjerke, PhD, Mattias Göthlin, MSc, Carl Eckerström, MD, PhD, Anders Wallin, MD, PhD  
*Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden*

- P52** **EFFECTS OF BIOMARKERS ON COGNITIVE DOMAINS IN ALZHEIMER'S DISEASE**  
Opler M (1,3), Yavorsky C (1,2), [Rothman B](#) (1), Lucic L (1,4), Khan A (1,5)  
(1) *ProPhase, LLC*, (2) *CROnos CCS*, (3) *New York University School of Medicine*, (4) *Pratt Institute*, (5) *Nathan S. Kline Institute for Psychiatric Research*

- P53** **DIFFERENTIAL ITEM FUNCTIONING AND THE ALZHEIMER'S DISEASE ASSESSMENT SCALE-COGNITIVE (ADAS-COG) AMONG PATIENTS WITH ALZHEIMER'S DISEASE**  
Yavorsky C (1,2), Khan A (1,5), Opler M (1,3), [Lucic L](#) (1,4), Rothman, B (1)  
(1) *ProPhase, LLC*, (2) *CROnos CCS*, (3) *New York University School of Medicine*, (4) *Pratt Institute*, (5) *Nathan S. Kline Institute for Psychiatric Research*

- P54** **ALTERATIONS IN VASCULAR FUNCTION IN ALZHEIMER'S DISEASE AND ACROSS THE ADULT LIFESPAN**  
Sarah Catchlove, PhDc, Andrew Pipingas, PhD, [Helen Macpherson](#), PhD  
*Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia*

## THEME: HEALTH ECONOMICS AND CLINICAL TRIALS

- P55** **LIVING ALONE IN ALZHEIMER'S DISEASE—THE INFLUENCE OF FUNCTIONAL IMPAIRMENT**  
[Carina Wattmo](#), RN, BSc, PhD, Lennart Minthon, MD, PhD, Åsa K. Wallin, MD, PhD  
*Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden*

- P56** **CANCELLED**

# POSTER PRESENTATIONS

## THEME: EPIDEMIOLOGY AND CLINICAL TRIALS

### **P57** CHARACTERISTICS OF PATIENTS RECENTLY DIAGNOSED WITH ALZHEIMER'S DISEASE: A 3.5-YEAR TIME-COURSE ANALYSIS

Kasem Akhras (1), Baoguo Jiang (1), Beenish S. Manzoor (2), [Shawn Yu](#) (1), Jiao Yang (1)  
(1) Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, (2) University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA

### **P58** SHARING DATA FROM ONGOING TRIALS TO BETTER DESIGN NEW AD PREVENTION TRIALS: THE HEALTHY AGING THROUGH INTERNET COUNSELING IN THE ELDERLY (HATICE) PROJECT

[Sandrine Andrieu](#) (1,2,3,4), Nicola Coley (1,2,4), Miia Kivipelto (5,6,7), Francesca Mangialasche (5), Tiia Ngandu (7), Yannick Meiller (8), Juliette Guillemont (1,2,8), Abraham van de Groep (9), Eric P. Moll van Charante (10), Carol Brayne (11), Hilikka Soininen (6,12), Willem A van Gool (13), Edo Richard (13) for the HATICE consortium  
(1) INSERM U1027, Toulouse, France, (2) University of Toulouse III, Toulouse, France, (3) Dept of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France, (4) Gerontopole, Toulouse University Hospital, Toulouse, France, (5) Aging Research Center, Dept. of Neurobiology, Health Care Sciences and Society, Karolinska Institute, Stockholm, Sweden, (6) Dept. of Neurology, University of Eastern Finland, Kuopio, Finland, (7) Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland, (8) NOVAPTEN, (9) VitalHealth Software, (10) Dept. of General Practice, Academic Medical Centre, University of Amsterdam, The Netherlands, (11) Department of Public Health and Primary Care, Institute of Public Health, Cambridge, UK, (12) Department of Neurology, Kuopio University Hospital, Kuopio, Finland, (13) Dept. of Neurology, Academic Medical Centre, University of Amsterdam, The Netherlands

## THEME: ANIMAL MODELS AND CLINICAL TRIALS

### **P59** HYPERTHERMIA EXACERBATES AMYLOID-BETA PEPTIDE INFUSION INDUCED ALZHEIMER'S DISEASE PATHOLOGY AND BEHAVIORAL DISTURBANCES

Aruna Sharma, MD (1), Dafin F Muresanu, MD, PhD (2), Rudy J Castellani, MD, Ph D (3), Mark A Smith, MD, Ph D (4), Hari S Sharma, MD, Ph D, Dr Med Sci (5)  
(1) Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Sweden, (2) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, (3) University of Maryland, Dept. of Pathology, Baltimore, MD, USA, (4) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, (5) Dept. Surg Sciences, Anesthesiology & Intensive Care medicine, University Hospital, Uppsala University, Uppsala, Sweden

### **P60** 5-LIPOXYGENASE PHARMACOLOGICAL BLOCKADE DECREASES TAU PHOSPHORYLATION IN VIVO: INVOLVEMENT OF THE CYCLIN-DEPENDENT KINASE-5

[Jin Chu](#), Domenico Pratico  
Temple University, Philadelphia PA, USA

### **P61** EFFECTS OF ELND005 (SCYLLO-INOSITOL) AND CLOZAPINE ON SOCIAL WITHDRAWAL BEHAVIORS: DIFFERENTIAL PROFILES IN A PCP ANIMAL MODEL

[Paul Shughrue](#), PhD (1), Allison Whalen (1), Kevin Quinn, PhD (2), Susan Abushakra, MD (2), Gene Kinney, PhD (1)  
(1) Prothena Biosciences, South San Francisco, CA, USA, (2) Elan Pharmaceuticals, San Francisco, CA USA

### **P62** EARLY GLUTAMATERGIC DYSFUNCTION IN A MOUSE MODEL OF FAMILIAL ALZHEIMER'S DISEASE

[Jinghua Jin](#) (1), [Sanh H. Luu](#) (1), [Kelly Tseng](#) (1), [Karen Gylys](#) (1,2), [Sophie Sokolow](#) (1,2,3)  
(1) UCLA School of Nursing, (2) UCLA Brain Research Institute, (3) UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

### **P63** APP DOSAGE CAUSES SLEEP DISTURBANCES IN A GENETIC MODEL OF DOWN SYNDROME

[Damien Colas](#), PhD (1), [Chuluun Bayarsaikhan](#), MD, PhD (1), [Hagiwara Grace](#) (1), [Moblely William](#), MD, PhD (2), [Heller HC](#), PhD (1)  
(1) Department of Biology, Stanford University, Stanford, CA, USA, (2) Department of Neurosciences, UCSD, San Diego, CA, USA

### **P64** POTENTIAL ROLE OF OREXIN IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE

[Jee Hoon ROH](#) (1,2), [Ashish HEDA](#) (2), [Mary Beth FINN](#) (2), [Tom MAHAN](#) (2), [Mingjie LI](#) (2), [Seiji NISHINO](#) (3), [Luis DE LECEA](#) (3), [Masashi YANAGISAWA](#) (4), [David HOLTZMAN](#) (2)  
(1) Department of Neurology, Asan Medical Center, Seoul, Korea, (2) Department of Neurology, Washington University School of Medicine, MO, USA, (3) Psychiatry and Behavioral Sciences, Stanford University, CA, USA, (4) Molecular Genetics, UT Southwestern, TX, USA

# POSTER PRESENTATIONS

## THEME: NEW THERAPIES AND CLINICAL TRIALS

- P65** **EFFECTS OF TREATMENT WITH SOLANEZUMAB IN PATIENTS WITH ALZHEIMER'S DISEASE WHO RECEIVE CURRENT STANDARD OF CARE**  
Vicki Poole Hoffmann, PharmD, Michael Case, MSc, Ann Marie Hake, MD1  
*Neuroscience, Eli Lilly and Company, Indianapolis, IN, USA*
- 
- P66** **THE INTEGRATIVE TREATMENT IN THE CONTEXT OF THE PRESERVATION OF THE COGNITIVE PERFORMANCE IN ALZHEIMER PATIENTS**  
Gjumrakch Aliev, MD, PhD (1,2), Ilya Bragin, MD (3), Valentin Bragin, MD, PhD (4)  
(1) GALLY International Biomedical Research Consulting LLC., San Antonio, Texas, USA, (2) School of Health Science and Healthcare Administration, University of Atlanta, GA, USA, (3) Upstate Medical University, New York, NY, USA, (4) Stress Relief and Memory Training Center, Brooklyn, NY, USA
- 
- P67** **APPLICATION OF TAI CHI 6-FORM SPORT APPARATUS IN PATIENTS WITH ALZHEIMER'S DISEASE**  
Alice M.K. Wong MD (1,2), Yu-Ting Chiu MS (1), Chia-Wei Wang PT MS (1), Yu-Cheng Pei MD PhD (1,2), Wen-Chuin Hsu MD PhD (3)  
(1) Department of Rehabilitation Medicine & Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, (2) Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan, (3) Chang Gung Dementia Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 
- P68** **HUMAN PHOTOSYNTHESIS AND ALZHEIMER'S DISEASE**  
Arturo Solís Herrera, MD, Ph.D  
*Human Photosynthesis Study Center, Aguascalientes, Mexico*
- 
- P69** **DIABETES EXACERBATES ALZHEIMER'S DISEASE INDUCED BRAIN PATHOLOGY. POSSIBLE NEUROPROTECTIVE EFFECTS OF CEREBROLYSIN**  
Hari S. Sharma (1), Dafin F. Muresanu (2), Rudy J Castellani (3), Mark A Smith (4), Ranjana Patnaik (5), Herbert Mössler (6), Aruna Sharma (1)  
(1) Cerebrovascular Research Laboratory, Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine University Hospital, Uppsala University, Uppsala, Sweden, (2) Department of Pathology, University of Maryland, Baltimore, MD, USA, (3) Dept. of Clinical Neurosciences, University Hospital, University of Medicine & Pharmacy, Cluj-Napoca, Romania, (4) Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 5125, 2103 Cornell Road, Cleveland, Ohio 44106 USA, (5) Department of Biomaterials, School of Biomedical Engineering, National Institute of Technology, Banaras Hindu University, Varanasi-221005, India, (6) Ever NeuroPharma, Unterach, Austria
- 
- P70** **THE USE OF HIGH CONTENT CELLULAR ANALYSIS TO IDENTIFY KENPAULLONE AS AN EFFECTIVE COMPOUND IN DIRECTING NEURAL STEM CELL DIFFERENTIATION**  
Xiangjian Luo, PhD, Zheng Yin, Dongbing Gao, Xiaofeng Xia, Stephen TC Wong  
*Department Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Houston, TX - USA*
- 
- P71** **MULTILEVEL EVALUATION OF AN ANDEAN SHILAJIT BASED COMPOUND**  
Gonzalo A. Farías, MD, PhD (1,2), Leonardo Guzmán (1), George Perry, PhD (3), Ricardo B. Maccioni, PhD (1)  
(1) International Center for Biomedicine (ICC), Avda. Vitacura 3568, Vitacura, Santiago, Chile, (2) Department of Neurology and Neurosurgery, Faculty of Medicine, Universidad de Chile, Santiago, Chile, (3) College of Sciences, University of Texas, San Antonio, TX, USA
- 
- P72** **IMPACT OF PRESENILIN/GAMMA-SECRETASE DEGRADATION OF EXTRACELLULAR AB42**  
Naoki Mizuta, MD, Masayasu Okochi, MD, PhD, Shinji Tagami, MD, PhD, Kanta Yanagida, PhD, Takashi Kodama, PhD, Masatoshi Takeda, MD, PhD  
*Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan*
- 
- P73** **XYLOCOSIDE G REDUCES AMYLOID-B INDUCED NEUROTOXICITY THROUGH INHIBITING NF-KB SIGNALING PATHWAY**  
Dehua Chui (1), Ting Zhou (1), Tao Zhang (1), Hecheng Wang (1), Yawei Tong (1), Yan Yu (1), Pengfei To (2)  
(1) Neuroscience Research Institute & Department of Neurology, Third Hospital, Peking University, China, (2) The State Key Laboratory of Natural and Biomimetic Drugs, Health Science Center, Peking University, China
-

# POSTER PRESENTATIONS

## THEME: NEW THERAPIES AND CLINICAL TRIALS

- P74** **WHY AMYLOID THERAPY WON'T CURE ALZHEIMER'S DISEASE AND IS A WASTE OF TIME AND PUBLIC FUNDS?**  
Alexei Koudinov, MD, PhD, DrSci (1,2,3), Natalia Shishkova, MD, PhD, DrSci (1,2), Temirbolat Berezov, MD, PhD, DrSci (1,2)  
*(1) Biochemistry, TT Berezov Laboratory, Russian People Friendship University, (2) Orekhovich Institute of Biomedical Chemistry, Moscow, Russia, (3) Neurobiology of Lipids, Rehovot, Israel*
- 
- P75** **FYN KINASE INHIBITION BY SARACATINIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE: RATIONALE, PRECLINICAL SUPPORT AND PHASE 1B TRIAL DESIGN**  
Haakon B. Nygaard, MD, PhD (1,2), Ji Won Um, PhD (1), Adam C. Kaufman, BS (1), Christopher van Dyck, MD (3), Stephen M. Strittmatter, MD, PhD (1,2)  
*(1) Cellular Neuroscience, Neurodegeneration and Repair Program(CNNR), Yale University, New Haven, CT, USA, (2) Department of Neurology, Yale University, New Haven, CT, USA, (3) Department of Psychiatry, Yale University, New Haven, CT, USA*
- 
- P76** **AN OBSERVATIONAL STUDY IN OUTPATIENTS AND NURSING HOME RESIDENTS WITH ALZHEIMER'S DISEASE TREATED WITH ORAL OR TRANSDERMAL MONOTHERAPY TO EVALUATE COMPLIANCE, TREATMENT OUTCOME AND CAREGIVER SATISFACTION**  
Mathieu Ceccaldi, MD, PhD (1), Pierre Jouanny, MD (2), Olivier Guerin, MD (3), Alain Bredin, MD (4), Jean Jacques Pere, MD (5), Isabelle Bourdeix, PhD (5)  
*(1) CHU Timone, Marseilles, France, (2) CHU Amiens, France, (3) CHU Nice, France, (4) Blaye, France, (5) Novartis Pharma Rueil- Malmaison France*

# General Information

## Congress Venue

### Westin Gaslamp Quarter

910 Broadway Circle  
San Diego, California 92101



### Practical details:

Registration desk opening hours:

- *Thursday, November 14<sup>th</sup>*  
7:00 am - 6 pm
- *Friday, November 15<sup>th</sup>*  
7:30 am - 5:30 pm
- *Saturday, November 16<sup>th</sup>*  
7:30 am - 12:30 pm

### CME credits:

Please come see us at the Management desk to obtain your CME certificate. Remember to fill out the overall evaluation and daily evaluations (both in your attendee bag) to obtain your certificate in order to abide by CME guidelines.

## Welcome Reception Thursday, November 14

Hosted by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego, CtaD 2013 welcomes you to an evening of networking and relaxation at the Omni Hotel San Diego where from its Palm Terrace you will take in the extraordinary views of the San Diego Bay, the downtown skyline and the Gaslamp Quarter.

Buses will depart at 6:30 pm from the Westin Gaslamp and return attendees directly to the hotel afterwards.

### Omni San Diego Hotel

675 L Street  
San Diego, California 92101



### OUR LOCAL PARTNER

The Alzheimer's Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer's disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neuroscience's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer's Disease Prevention Initiative.

More at [www.adcs.org](http://www.adcs.org)

# Continuing Medical Education

This UCSD School of Medicine accreditation and its designated number of CME credits are recognized by all the national authorities of the countries of the European Union. Individual physicians are awarded the designated number of corresponding European credits by the European Accreditation Council for Continuing Medical Education EACCME.

In order to claim your credits for this event, please fill out the overall and daily evaluations in your attendee bags. Certificates will be available at the Conference Management desk at the end of the event.

## Course Description

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer's disease drugs is becoming essential to face up to this challenge. New pathways have been identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.

However, methodological challenges continue to slow the development of specific new drug candidates. One of the objectives of the conference is to identify these hurdles and find ways to address them by bringing together world leaders in AD drug development to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

## Target Audience


The target audience for CtaD2013 includes neurologists, psychiatrists and other clinicians and scientists involved in geriatric care, research, imaging and drug development for patients with Alzheimer's disease and other neurodegenerative disorders. Other healthcare professionals who may benefit from this activity are clinical research coordinators, nurses, speech therapists and other AD and dementia occupational therapists, psychologists and neuropsychologists.

## CTAD 2013: Learning objectives

During this event essential learning objectives will be covered so that at the end of the conference each participant should be able to:

1. Translate the significance to the drug development process of each individual phase of clinical trials from Phase I to Phase IV.
2. Articulate the involvement of neurotransmitters and cortical excitability in Alzheimer's disease pathology, and the implications for treatment.
3. Interpret back outcomes of APOE4-related therapeutic strategies.
4. Identify and evaluate interdisciplinary approaches combining biochemistry, molecular and cell biology, and transgenic modeling to unveil AD molecular mechanisms.
5. Describe new drug combination therapies under study and their future applications in the field of AD.
6. Implement in research studies: cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.
7. Interpret back valuable information on new upcoming molecules in order to educate fellow physicians and propose alternatives to patients.
8. List the novel methodologies or biomarkers essential in identifying predementia patients most at risk of developing AD.
9. List study findings, including safety, biomarker and clinical findings, presented at the conference underlying progress in understanding the amyloid hypothesis.





10. Describe new composite outcome scores that optimize the power for measuring clinical disease progression for trials in a MCI and pre-MCI populations.
11. Describe and interpret sensitive biochemical (e.g. CSF A-beta, tau and phospho tau levels) and neurophysiological (e.g. QEEG, ERP) biomarkers of early AD detection.
12. Interpret ERP data in AD clinical trials and drug development for cohort selection and monitoring disease progression.
13. Identify and evaluate new methods for optimally scoring each patient's test item responses and overall test performance, for determining the number of dimensions underlying the test's performance, and for adjusting for sample bias effects.
14. Interpret back AD impact in other populations like Down Syndrome.
15. Express appreciation for vertical integration and the impact it can have by improving knowledge transfer and drug development.

### **Needs Assessment**

CTAD 2013 Scientific committee identified several practice gaps in designing and conducting AD Clinical Trials and developed the program to address these gaps, namely:

- The need to appreciate the full spectrum of AD from an asymptomatic stage through dementia
- The need for learning how dementia can affect specific population subgroups
- The need to elucidate risk factors for AD and other dementias
- The need to identify and avoid methodological errors in the design of multicenter and international clinical trials
- The need for improved measurement of cognitive deficits
- The need to keep up with scientific advances regarding biomarkers of AD pathologies.

Beyond these global practice gaps addressed throughout the conference other essential learning objectives will be covered so that at the end of the conference each participant will be able to understand:

- The importance of each individual phase of clinical trials from Phase I to Phase IV
- The relevance of neurotransmitters and cortical excitability in Alzheimer's disease pathology
- The cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.

### **Accreditation statement:**

The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **Credit designation statement:**

The University of California, San Diego School of Medicine designates this live activity for a maximum of *18.0 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Cultural and Linguistic Competency Statement:**

California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which may be included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at <http://cme.ucsd.edu>.



# Faculty List

## Course Directors

Paul S. Aisen, MD  
Alzheimer's Disease Cooperative Study (ADCS)  
Department of Neurosciences  
UCSD School of Medicine  
San Diego, USA

Jacques Touchon, MD, PhD  
Chair of the Department of Neurology  
Montpellier University Hospital  
INSERM U1061  
Montpellier, France

Bruno Vellas, MD, PhD  
Toulouse University Hospital  
Department of Neurology  
Toulouse, France

Michael Weiner, MD  
University of California at San Francisco,  
San Francisco, USA

## UC San Diego

Colin Ard, PhD  
Department of Neurosciences  
UCSD School of Medicine

William Mobley, MD, PhD  
Professor and Chair  
Department of Neurosciences  
UCSD School of Medicine

Robert Rissman, PhD  
UCSD Health Sciences  
Department of Neurosciences  
UCSD School of Medicine

## Visiting Faculty

Erin Abner, PhD  
Sanders-Brown Center on Aging  
University of Kentucky  
Lexington, KY, USA

Susan Abushakra MD  
VP Global Development  
AD Program Leader  
Elan Pharmaceuticals  
S. San Francisco, CA, USA

Michael G. Agadjanyan, PhD  
Department of Molecular Immunology  
Institute for Molecular Medicine  
Huntington Beach, CA, USA  
Institute for Memory Impairments  
and Neurological Disorders  
University of California at Irvine  
Irvine CA, USA

Bruce Albala, PhD  
Eisai Inc.,  
Woodcliff Lake, NJ, USA

Raymond Bartus, PhD  
RTBioconsultants, Inc.  
San Diego, CA, USA

Martina Bocchetta, MD  
LENITEM (Laboratory of Epidemiology,  
Neuroimaging and Telemicine)  
IRCCS – S. Giovanni di Dio  
Fatebenefratelli Brescia, Italy

Randall Bateman, MD, PhD  
Washington University  
School of Medicine  
St Louis, MO, USA

John Breitner, MD, MPH  
Centre for Studies on Prevention of AD McGill  
University Faculty of Medicine  
Montreal, Québec, Canada

Alexandre Castellano  
Research Center on Aging and Department of  
Medicine, University of Sherbrooke  
Quebec, Canada

Marco Cecchi, PhD  
Neuronetrix  
Louisville, KY, USA

Yun-Fei Chen, PhD  
Neuroscience  
Eli Lilly and Company  
Indianapolis, IN, USA

Jeffrey Cummings, MD  
Cleveland Clinic Lou Ruvo Center for  
Brain Health  
Las Vegas, NV, USA

Jean-François Dartigues, MD, PhD  
INSERM U897  
Epidemiology and Biostatistics Unit,  
CMRR Bordeaux-Pellegrin  
Bordeaux, France

Julien Delrieu, MD  
Toulouse Alzheimer's Disease Research Clinical  
Center - Gérontopôle,  
Toulouse, France

Bruno Dubois, MD, PhD  
Department of Neurology Salpêtrière Hospital  
Paris, France

Larry Ereshefsky  
PharmaD PAREXEL  
International Glendale, CA, USA

Milan Fiala, MD  
Surgery Department UCLA  
Los Angeles, CA, USA

Massimo S. Fiandaca, MD  
Dpts of Neurology and Neuroscience  
Georgetown University Medical Center  
Washington, DC, USA

Audrey Gabelle, MD  
Department of Neurology  
University Hospital Gui de Chauiac  
Montpellier, France

Katherine R. Gray, PhD  
IXICO Ltd  
London, United Kingdom

Serge Gauthier, MD  
McGill Center for Studies in Aging,  
Douglas Mental Health Research Institute  
Montreal, Canada

John Harrison, PhD  
Polyhymnia Translational Research  
Metis Cognition, Ltd.  
Dept. of Medicine, Imperial College,  
London, UK

Samuel T Henderson, PhD  
Accera Inc  
Broomfield, CO, USA

Suzanne Hendrix, PhD  
Pentara Corporation,  
Salt Lake City, UT, USA

Christophe Hirtz, PhD  
INSERM U1040  
Clinical Proteomics Biochemical Lab  
Montpellier, France

Akihiro Hisaka, PhD  
Pharmacology and Pharmacokinetics  
The University of Tokyo Hospital  
Tokyo, Japan

David Holtzman, MD  
Alzheimer's Disease Research Center  
Washington University in St. Louis  
St. Louis, MO – USA

Jordan Holtzman MD, PhD  
Departments of Pharmacology, Division of Environ.  
Health Sciences  
University of Minnesota,  
Minneapolis, MN, USA

Jacques Hugon, MD, PhD  
Hôpital Lariboisière  
INSERM U 839  
Paris, France

Judith Jaeger, MD  
CogState, Inc.  
New Haven, CT, USA  
Albert Einstein Coll of Medicine  
Bronx, NY, USA

Jan Johansson  
Karolinska Institutet  
Stockholm, Sweden

Keith A. Johnson, MD  
Massachusetts General Hospital  
Harvard Medical School  
Boston, MA, USA

Charles Kerbage, PhD  
Cognoptix, Inc.  
Acton, MA, USA

Nzeera Ketter, MD  
Janssen Alzheimer Immunotherapy R&D  
South San Francisco, CA - USA

Nicholas Kozauer, MD  
Food and Drug Administration,  
Silver Spring, MD, USA

Robert Krikorian, PhD  
Department of Psychiatry & Behavioral  
Neuroscience  
University of Cincinnati  
Academic Health Center  
Cincinnati, OH, USA

Amit Lampit  
Regenerative Neuroscience Group Brain and Mind  
Research Institute University of Sydney  
Sydney, Australia

Andreas Langer, PhD Molecular Pharmacology Unit  
Swiss Federal Institute of Technology  
Zurich, Switzerland

Valérie Legrand, PharmD  
ICON  
Paris, France

Veronika Logovinsky, MD, PhD  
Eisai Inc.  
Neuroscience Product Creation Unit  
Woodcliff Lake, NJ, USA

Prisca Lucas, PharmD, PhD  
Pfizer PGRD  
Paris, France

Richard A Margolin MD  
Alzheimer's disease Neuroimaging Initiative  
Janssen Alzheimer Immunotherapy LLC,  
South San Francisco, CA, USA

Paul Maruff, MD  
CogState Ltd  
The Florey Institute of Neuroscience and Mental  
Health  
Parkville, Victoria, Australia

Mark A. Mintun, MD  
Avid Radiopharmaceuticals, Inc  
Philadelphia, PA, USA

Lisa Mosconi, PhD  
Assistant professor of Psychiatry  
PET Imaging Research Director, Center for Brain  
Health  
New York U School of Medicine  
New York, NY, USA

Anne M. Murray, MD  
Department of Medicine and Geriatrics  
Hennepin County Medical Center  
Minneapolis, MN USA

Omnia Nayel, MD, PhD  
Pharmacology department  
Faculty of Medicine  
King Saud University  
Riyadh, KSA

Joonmi Oh, MD  
Synarc Inc  
Newark, NJ, USA

Nobuyuki Okamura, MD, PhD  
Department of Pharmacology  
Tohoku University School of Medicine  
Sendai, Japan

Masayasu Okochi, MD, PhD  
Department of Psychiatry  
Osaka University Graduate School of Medicine  
Osaka, Japan

Pierre-Jean Ousset, MD  
CenGeps Alzheimer Drug Trial Network,  
Gerontopole  
Toulouse, France

Harish C. Pant, MD  
Senior Investigator, NINDS / NIH  
Bethesda, MD, USA

Robert Paul, PhD  
Genentech  
South San Francisco, CA, USA

Pedro Pesini, PhD  
Araclon Biotech Ltd.  
Zaragoza. Spain

Ronald C. Petersen, MD, PhD  
Mayo Alzheimer's Disease Research Center  
Mayo Clinic  
Rochester, MN, USA

Anton P. Porsteinsson, MD  
Department of Psychiatry  
University of Rochester  
Rochester, NY, USA

Eric Reiman, MD  
Executive Director  
Banner Alzheimer's Institute  
Phoenix, AZ, USA

Dorene M. Rentz, PsyD  
Departments of Neurology, Massachusetts General  
Hospital and Brigham and Women's Hospital  
Boston, MA, USA

Michael T. Ropacki, PhD  
Neurology Department  
Loma Linda University  
Janssen Research & Development, LLC,  
San Francisco, CA, USA

Allen D. Roses, MD  
Zinfandel Pharmaceuticals, Inc.,  
Duke Bryan ADRC  
Durham, NC, USA

Mark Schmidt, MD  
Janssen Alzheimer Immunotherapy  
Research and Development  
Beerse, Antwerp, Belgium

Lon Schneider, MD  
AD Research and Clinical Center  
Department of Psychiatry Geriatric Studies Center  
University of Southern California  
Los Angeles, CA, USA

David Scott, PhD  
Synarc, Inc.  
Newark, CA, USA

Kohkan Shamsi MD, PhD  
RadMD  
New York, NY, USA

William R. Shankle, MS MD FACP  
Shankle Clinic Newport Beach, CA  
Department of Cognitive Sciences,  
UC Irvine, Irvine, CA, USA

Hong Liu-Seifert, PhD  
Lilly Research Laboratories  
Lilly Corporate Center  
Indianapolis, IN, USA

Jeanne Stemmelin, PhD  
Sanofi Research and Development  
Chilly Mazarin, France

Duygu Tosun, PhD  
Dpt of Radiology and Biomedical Imaging - UCSF  
San Francisco, CA, USA

Michael Valenzuela, PhD  
Regenerative Neuroscience Group Brain and Mind  
Research Institute University of Sydney  
Sydney, Australia

Carina Wattmo, RN, BSc, PhD  
Clinical Memory Research Unit  
Department of Clinical Sciences,  
Lund University  
Malmö, Sweden

Keith Wesnes PhD  
Bracket Global  
Goring on thames, UK  
Swinburne University  
Melbourne, Australia


Dieter Willbold, PhD  
Forschungszentrum Jülich,  
Jülich, Germany  
Heinrich-Heine-Universität Düsseldorf  
Institut für Physikalische Biologie,  
Düsseldorf, Germany

Robin Wolz, PhD  
IXICO Ltd  
Imperial College London  
London, UK

# Disclosure summary

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

SPEAKER NAME	NAME OF COMMERCIAL INTEREST	NATURE OF RELEVANT RELATIONSHIP <i>Employee, Grants/Research support recipient, Board Member, Advisor or Review Panel Member, Consultant, Independent Contractor, Stock Shareholder (excluding mutual funds), Speakers' Bureau, Honorarium recipient, Royalty recipient, Holder of Intellectual Property Rights or Other</i>	Will refrain from making recommendations	Will use "best available evidence"	Alternative presenter	Divested
Susan Abushakra	Elan Pharmaceuticals, Inc	Full-time employee and stock shareholder	x	x		
John Alam	Sanofi	Employee	x	x	x	
Bruce Albala	Eisai Inc  CogState	I am a full-time employee of and responsible for the development and clinical program to develop the new chemical entity. As a representative of Eisai Inc I am providing funding to CogState Ltd for the computer battery and related services as part of an ongoing investigational clinical trial.	x	x		
Gustavo Alva	<ul style="list-style-type: none"> <li>Accera, Cognoptix, Merck, Novartis, Tau Rx, Janssen, Pfizer, Otsuka, Lundbeck and Forest</li> <li>Takeda</li> </ul>	<ul style="list-style-type: none"> <li>Grants/Research Support recipient and Speaker's Bureau</li> <li>Speaker's Bureau</li> </ul>	x	x		
H.Michael Arrighi	Janssen Alzheimer Immunotherapy	Employee	x	x		
Mark Austin	Ixico	Employee			x	
Clive Ballard	Lundbeck	Research funding for King's College London and Honorarium recipient	x	x	x	x
Raymond T. Bartus	Sangamo	Occasional consultant	x	x		
Tiffany Baumann	Ceregene, Inc	Employee		x		
Raphael Bejuit	Sanofi	Employee	x	x	x	
Sarah Berg	Neuronetrix	Employee	x	x		
Kaj Blennow	Kuyowa Kirin Pharma, Pfizer, Roche	Advisory board	x	x	x	x
Stephen Brannan	Takeda	Employee	x	x		
Robert Brashear	Janssen AI, LLC	Full-time employee	x	x		
Henry Brodaty	<ul style="list-style-type: none"> <li>Janssen, Lilly, Medivation, Sanofi, Servier</li> <li>Pfizer, Novartis, Janssen, Lundbeck, Nutricia</li> <li>Merck, Baxter, Lilly, Nutricia</li> </ul>	<ul style="list-style-type: none"> <li>Investigator</li> <li>Advisory Board</li> <li>Consultant</li> </ul>	x	x		
Andrew Budson	Neuronetrix	Site PI for clinical trial of Neuronetrix device	x	x		
Kumar Budur	Takeda	Employee	x	x		
Shauna Burkholder	Neuronetrix	Employee	x	x	x	
Daniel K. Burns	Zinfandel Pharmaceuticals Takeda	Full time employee Alliance with Zinfandel Pharmaceuticals	x	x		
Gerald Cagle	Cognoptix	Employee		x		
Anne Margrethe Cameron	Cognoptix	Consultant	x	x		
Pete Castelluccio	Eli Lilly and Company	Independent contractor	x			
Marco Cecchi	Neuronetrix	Employee	x	x		



William Cho	Genentech/Roche	Employee	x	x		
Ping-Chun Chiao	Biogen Idec	Employee	x			
Sophie Claudel	Sanofi	Employee	x	x		
Valérie Corp dit Gentil	Sanofi	Employee	x	x	x	x
Gerald Crans	Elan Pharmaceuticals LLC	Employee and Stock Shareholder	x	x		
Donna Crenshaw	Zinfandel Pharmaceuticals	Consultant	x	x		
Jeffrey Cummings	<ul style="list-style-type: none"> <li>Acadia, ADAMAS, Anavex, Avanir, Baxter, Bristol-Myers Squibb, Eisai, EnVivo, Genentech, GlaxoSmithKline, Eli Lilly, Lundbeck, Merck, Novartis, Otsuka Pfizer, Prana, QR Pharma, Resverlogix, Roche, Sonexa, Suven, Takeda, Toyoma</li> <li>Eli Lilly</li> <li>GE Healthcare, MedAvante</li> <li>ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, Neurokos</li> <li>Neuropsychiatric Inventory</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Grants and Research Support</li> <li>Consultant for assessment company</li> <li>Stockholder</li> <li>Copyright owner</li> </ul>	x	x		
Stephen Cunnane	Accera	Consultant	x	x		
Michael Devous	Avid Radiopharmaceuticals, Inc	Employee	x	x		
P. Murali Doraiswamy	<ul style="list-style-type: none"> <li>Neuronetrix</li> <li>Avid/Lilly</li> <li>Sonexa</li> <li>Accera, Danone, Cognoptix</li> <li>Genomind, Piramal, Targacept</li> <li>AbbVie</li> <li>Lundbeck/Takeda</li> <li>Clarimedix</li> <li>Neurocog trials</li> </ul>	<ul style="list-style-type: none"> <li>Grants, Advisor</li> <li>Grants</li> <li>Advisor, Stockholder</li> <li>Advisor</li> <li>Advisor/Speaker</li> <li>Stockholder</li> <li>Consultant</li> </ul>	x	x		
Julien Dumurgier	Novartis	Travel expenses	x	x		
Noel Ellison	Eisai, Roche, Janssen	Independent contractor	x	x		
Larry Ereshefsky	Parexel	As a global CRO we have conducted clinical trials for most Pharma across an array of compounds for neurodegenerative disorders, including Alzheimer's Disease. Additionally, our early phase units (Los Angeles and Baltimore), wholly owned by PAREXEL, have conducted more than 10 studies over the past two years in Neurodegenerative Disorder indications supported by various sponsors including large and small pharma, Michael J Fox Foundation, and NIH.	x	x		
Claire Evans	Ichor Medical Systems	Employee	x			
Christine Fauveau	Sanofi	Employee	x			
Milan Fiala	Smartfish, Oslo, Norway	Honorarium recipient	x	x		
Denis Fortier	Medical Care Corporation	Employee, Board Member, Stock Shareholder			x	
Michel Friesenhahn	Genentech	Employee			x	
Shozo Furumoto	GE Healthcare Clino	Grants/Research support recipient Consultant	x	x		
Joanne Gale	CogState	Employee				x
Serge Gauthier	Eli Lilly and company	Speaker at international conferences	x	x		
Michelle Gee	Eisai Limited	Full-time employee	x	x		
Katherine Gray	Ixico Ltd.	Employee	x	x		
Keith Gregg	Janssen AI	Employee, stock shareholder	x	x		
Kennan Gu	Eisai	Employee	x	x		
Volkmar Guenzler	Janssen Alzheimer Immunotherapy	Employee	x	x		
Baoguang Han	Eli Lilly and company	Employee	x	x		
Kristin Hannesdottir	AtraZeneca	Employee	x			
Jutta Hänninen	Orion Corporation	Employee			x	x
Junko Hara	Medical Care Corporation	Employee, Board Member, Stock Shareholder	x			
John Harrison	Bracket Eisai	Independent contractor Consultant	x			
Samuel T.Henderson	Accera	Employee	x	x		
Suzanne Hendrix	Pentara Corporation	Independent contractor	x	x		
Karl Herholz	AVID Radiopharmaceuticals GE Healthcare	Research Grant Consultant	x	x		
Derek Hill	Ixico	Employee and board member and shareholder	x	x		
Akiro Hisaka	<ul style="list-style-type: none"> <li>Takeda Pharmaceuticals</li> <li>MSD Co. Towa Pharmaceutical</li> <li>Daiichi-sankyo Co.</li> <li>Eisai, Chugai Pharmaceutical, Kyowa Hakko</li> <li>Kirin Co.</li> <li>Mitsubishi Tanabe Pharm Co.</li> </ul>	Lab donation (supported by 8 companies)				x
Carole Ho	Roche	Stock shareholder				

Vicky Hoffmann	Eli Lilly and Company	Employee and stock shareholder	x	x		
David Holtzman	C2N Diagnostics	Co-founder and member of the scientific advisory board. C2N Diagnostics has licensed technology from Washington University that will be discussed. This technology is not yet in humans	x	x		
Judith Jaeger	CogState	Employee	x	x		
William Jagust	Synarc	Consultant	x	x		
Jan Johansson	AlphaBeta AB	Founder. Research support.	x	x		
Abhinay Joshi	Avid Radiopharmaceuticals, Inc	Employee	x	x		
Yokozuka Kazutoshi	Bell Medical Solutions Inc.	Employee of Bell Medical Solutions Inc. which contracted a part of this research from University of Tokyo Hospital	x	x		
Gene Kinney	Elan Pharmaceuticals	Previous employee and current shareholder	x	x		
Charles Kerbage	Cognitoix	Employee				x
Patrick Kesslak	Elan Pharmaceuticals LLC	Employee and Stock Shareholder	x	x		
Nzeera Ketter	Janssen Alzheimer Immunotherapy	Employee	x	x		
Stephane Kirkesseli	Sanofi	Employee	x	x		
Hartmuth Kolb	Avid Radiopharmaceuticals	Employee	x	x		
Jeffrey Kordower	Ceregene Inc	Scientific advisor	x	x		
Yukitsuka Kudo	GE Healthcare Clino	Grants/research support recipient Board member, stock shareholder (excl. mutual funds)	x	x		
Matthias Kurth	Elan Pharmaceuticals LLC	Employee	x	x		
Robert Y K Lai	Eisai	Employee	x	x		
Jessica Langbaum	National Institute on Aging	1RF1AG041705-01A1	x	x		
David Li	Pfizer	Employee	x	x		
Enchi Liu	Janssen Alzheimer Immunotherapy	Employee	x	x		
Hong Liu-Seifert	Eli Lilly and Co.	Employee	x	x		
Kasia Lobello	Pfizer	Employee	x			
Veronika Logovinsky	Eisai Inc.	Employee	x			
Ming Lu	Avid Radiopharmaceuticals, Inc	Employee	x	x		
Prisca Lucas	Pfizer, Inc.	Employee	x	x		
Ana Lukic	ADMdx	Employee	x	x		
Michael Lutz	Zinfandel Pharmaceuticals	Consultant	x	x		
Constantine Lyketsos	<ul style="list-style-type: none"> <li>NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation Inc., Janssen</li> <li>Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS</li> <li>Pfizer, Forest, Glaxo-Smith Kline, Health Monitor</li> </ul>	<ul style="list-style-type: none"> <li>Grant support (Research or CME)</li> <li>Consultant Advisor</li> <li>Honorarium or travel support</li> </ul>				
Richard Margolin	Janssen Alzheimer Immunotherapy R&D LLC	Employee	x	x		
Renata Martincova	Sanofi	Employee	x	x	x	x
Paul Maruff	CogState	Full-time employee	x			
Dawn Matthews	ADM Diagnostics LLC	CEO, stockholder, employee	x	x		
Kate McLeish	IXICO	Employee	x	x		
Agnes Menut	Sanofi	Employee	x			
Mark Mintun	Avid Radiopharmaceuticals, Inc.	Employee	x	x		
Richard Mohs	Eli Lilly and Co.	Full time employee and stockholder	x	x		
Kristen Morris	Elan Pharmaceuticals	Employee	x	x		
Dennis Nilan	Cognitoix	Employee				x
Nobuyuki Okamura	GE Healthcare Clino	Grants/Research support recipient Consultant, stock shareholder (excl. mutual funds)	x	x		
Jeffrey Ostrove	Ceregene, Inc	Employee, Stockholder	x			
Claire Paquet	Genentech	Employee	x	x		
Robert Paul	Genentech	Employee	x	x		
Pedro Pesini	Araclon Biotech Ltd.	Employee	x	x		

Ron Petersen	Pfizer, Inc, Janssen AI GE Healthcare	Chair Data Monitoring Committee Consultant	x	x		
Steven Potkin	Ceregene	Consultant				x
Anton Porsteinsson	Elan, Janssen AIP Avanir, Baxter BMS, EnVivo, Genentech/ Roche, Merck, Pfizer, Toyoma, Quintiles, Functional, Neuromodulation Forrest	Grant/Research Support, Consultant Grant/Research Support Consultant Speaker's Bureau	x	x		
Derk Purcell	Janssen Alzheimer's Immunotherapy	Consultant	x			x
Michael Ropacki	Janssen R&D	Employee	x			x
Allen D. Roses	Zinfandel Pharmaceuticals	CEO and President, a NC S-Corporation with 11 employees. Holder of Intellectual Property Rights In an Alliance with Takeda Pharmaceutical [Zinfandel-Takeda Alliance] as a strategic partner to design, plan and execute The TOMMORROW clinical trial and other related clinical trials using pioglitazone for delay of onset or treatment of MCI-AD.	x			x
Juha Rouru	Orion Pharmaceuticals	Employee	x			x
Daniel Rueckert	IXICO	Founder, Shareholder, Consultant	x			x
Carl Sadowsky	• Novartis, Lilly, Forest, Accera • Cognoptix • PamLab	• Advisory Board and Speakers' bureau • Advisory Board • Speakers' bureau	x			x
Manuel Sarasa	Araclon Biotech Ltd.	Employee and CSO	x			x
Andrew Satlin	Eisai, Inc.	Full-time employee	x			x
Ann M. Saunders	Zinfandel Pharmaceuticals	Wife of Allen Roses CEO and consultant	x			x
Adrian Schembri	CogState, Inc	Employee	x			x
Mark Schmidt	Janssen Pharmaceutica, NV	Full time employee of Janssen Pharmaceutica and scientific advisor to Janssen Alzheimer Immunotherapy	x			x
Lon Schneider	Toyama FujiFilm, En Vivo Novartis, AC Immune, Abbvie Baxter, Biogen Idec, Piramal Targacept, Tau Rx, Eli Lilly, Johnson and Johnson, Takeda and Zinfandel, Allon, Roche, AstraZeneca, AC Immune Merck	Consulting  Consulting and DMC	x			x
Adam Schwarz	Eli Lilly and Co.	Employee and shareholder	x			x
William Shankle	Medical Care Corporation	Employee, Board Member, Stock Shareholder				x
Sergey Shcherbinin	Eli Lilly and Company	Employee	x			x
Jeffrey Sevigny	Biogen Idec	Employee	x			x
Eric Siemers	Eli Lilly and Company	Employee and Shareholder	x			x
Joao Siffert	Ceregene Inc.	Former employee and stock shareholder	x			x
Daniel Skovronsky	Avid Radiopharmaceuticals Eli Lilly and Company	Employee				x
Adina Soaita	Cogstate	Employee	x			x
Jeanne Stemmelin	Sanofi	Employee	x			x
Robert Stern	Athena Diagnostics Janssen Alzheimer's Immunotherapy Janssen Alzheimer Immunotherapy R&D	Consultant Past research support for site clinical trial  Employee R&D	x			x
Stephen Strother	ADM Diagnostics	Part-owner and part-time employee of ADM Diagnostics where this modeling work was performed.				x
Scott Styren	Pfizer	Employee	x			x
David Sultzzer	Eli Lilly and Co., Otsuka Avanir, Elan	Research Support, consultant Consultant Research Support	x			x
Karen Sundell	Eli Lilly and Co.	Employee and minor stockholder	x			x
Hiroshi Suzuki	• Astellas Pharma, Pfizer Inc • MSD Co. Ltd., Towa Pharmaceuti- cal Co. Ltd., Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharm Corporation • Daiichi-Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd.	• Donation • Laboratory donation  • Donation and Laboratory donation				x
Chad Swanson	Eisai, Inc.	Full-time employee	x			x
Pierre Tariot	Genentech, Lilly/Abbott, NIH/NIA, Anony- mous Foundation, State of Arizona AC-Immune	Grant/Research support recipient Consultant	x		x	x
Michael Valenzuela	Brain Department Pty Ltd  Pfizer Neuroscience Australia	Research support and speaker's honoraria from The Brain Department Pty Ltd for work unrelated to this report. In-kind research support from BrainTrain for a study unrelated to this report. Research funding and speaker's honoraria from Pfizer Neuroscience Australia for work unrelated to this report.	x			x



Bruno Vellas	<ul style="list-style-type: none"> <li>Astra, Eisai, Elan, Exhonor, GSK, Lilly, Medivation, Nestlé, Nutricia, Pfizer, Pierre-Fabre, Roche, Sanofi, Servier, TauRx Therapeutics, Wyeth</li> <li>Avid, BMS, Elan, Exhonor, GSK, Ipsen, Lilly, Medivation, Pfizer, Pierre-Fabre, Roche, Servier, TauRx Therapeutics, Wyeth</li> </ul>	Board Member	x	x
		Grants/Research support recipient		
Aarti Verma	Elan Pharmaceuticals LLC	Employee and Stock Shareholder	x	x
Carina Wattmo	Novartis	Speaker honoraria		x
Michael Ward	Genentech	Employee	x	x
Keith Wesnes	Bracket Global	Employee and Stock Shareholder	x	x
Robin Wolz	IXICO, Ltd. Philips Healthcare	Consultant Employee	x	x
Miles Wernick	ADM Diagnostics	Chief Technical Officer	x	x
Deborah Yarbrough	Takeda	Employee	x	x

The following have no relevant financial relationships to disclose:

Said AbdAlla, Erin Abner, Michael Agadjanyan, Paul Aisen, Jonathan Alverio, H el ene Amieva, Randolph Andrews, Sandrine Andrieu, Peter Annas, Hiroyuki Arai, Colin Ard, Steven Arnold, Napatkamon Ayutyanont, Roy A.E. Bakay (deceased), Claudia Balducci, David Barba, Frederik Barkhof, Hans Basun, Randall Bateman, Corinna Bauer, Herve Bester, Kathie Bishop, Melanie Blair, Marina Boccardi, Martina Bocchetta, Thomas Brady, John Breitner, Emma Burton, Allison Caban-Holt, Anna Caroli, David Casey, Alexandre Castellano, Matthieu Ceccaldi, Kewei Chen, Yun-Fei Chen, Carl Chiang, Adam Christensen, Yaping Chu, Jack Clifford, David Cribbs, Arpine Davtyan, Hayk Davtyan, Jean-Fran ois Dartigues, Julien Delrieu, Ying Ding, Michael Donohue, Bruno Dubois, Marc Dubourdeau, Simon Duschesne, Steven Edland, Wassam El-Hadidy, Maha El-Tohamy, Massimo S. Fiandaca, Clarissa Ferrari, Adam Fleisher, Bradley Folley, Gianluigi Forloni, Melanie Fortier, Kristian Steen Frederiksen, Giovanni Frisoni, Xuebin Fu, Tamas Fulop, Katsutoshi Furukawa, Audrey Gabelle, Rossana Ganzola, Shannon Gardell, Anahit Ghochikyan, Michel Grothe, Cathleen Haense, Hariharan Hallock, Harald Hampel, Ryuichi Harada, Erik Hermansson, Christopher Herzog, Christophe Hirtz, Jordan Holtzman, Armine Hovakimyan, Jacques Hugon, Bradley Hyman, Aiko Ishiki, Ren Iwata, Gregory Jicha, Keith A. Johnson, Kelly Judge, Zaven Kachaturian, David Keator, Alana Kohn, Nicholas Kozauer, Robert Krikorian, Richard Kryscio, Sindy Kwok, Amit Lampit, Susan Landau, Andreas Langer, Stephane Lehericy, Val erie Legrand, Martin Lepage, Yawu Liu, Elisabet Londos, Francisco Lopera, Matthew Lukjanenko, Cindee Madison, Oliver Martinez, Moira Marizzoni, Melissa Matthews, Craig Metz, Yves Miaux, Edoardo Micotti, Lennart Minthon, William Mobley, Gilmour Morrison, Lisa Mosconi, Rebecca Moss, Setareh hajipour Moughadam, Anne Murray, Sharon Naismith, Omnia Nayel, Blandine Nembo, Masami Nishikawa, Scott Nugent, Joonmi Oh, Sheila O'Mahony, Masayasu Okochi, Pierre-Jean Ousset, Alessandra Paladini, Harish C. Pant, Patrizio Pasqualetti, Mary Pay, Rahul Peethala, Irina Petrushina, Marlie Philiossaint, Michael Pontecorvo, Marileen Portegies, Verna Porter, Greg Preboske, Annapaola Prestia, Jenny Presto, Ursula Quitterer, Mike Rafii, Eric Reiman, Dorene Rentz, J.O. Rinne Henry Riordan, Robert Rissman, Michael Rosser, Stephen Salloway, David Salmon, Cristina Sampaio, Frederick Schmitt, Aaron Schultz, David Scott, Daniel Seichepine, Kohkan Shamsi, Charles Smith, Paul Solomon, Reisa Sperling, Stephanie Stanworth, Travis Stoub, Stephen Strother, Joyce Suhy, Chung-Kai Sun, Tim Swihart, Manabu Tashiro, Ronald Thomas, Matthew Tinley, Naoki Tomita, Duygu Tosun, Jacques Touchon, Eric Turcotte, Scott Turner, Christopher van Dyck, Neil Vasdev, Sara Wade, Asa Wallin, Chadwick Ward, Michael Weiner, Kathleen Welsh-Bohmer, Dieter Willbold, Bengt Winblad, Dominik Wolf, Kazuhiko Yanai, Peng Yu, Yanke Yu.

**The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose.**

**This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.**



# Sponsors

Clinical Trials on Alzheimer's Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.

abbvie



GE Healthcare



ALZHEIMER'S  
IMMUNOTHERAPY PROGRAM  
INNOVATION TO REMEMBER™




Lilly



# Notes

A series of horizontal dashed lines for writing notes.



# *Notes*

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----



# Notes

Lined area for taking notes, consisting of multiple horizontal dashed lines.

# CTAD 2014

Clinical Trials on Alzheimer's Disease

Las Vegas '09 | Toulouse '10 | San Diego '11 | Monte Carlo '12 | San Diego '13

## Clinical Trials on Alzheimer's Disease

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Clinical Trials



November 20-22, 2014

Philadelphia



MONTPELLIER and TOULOUSE EADC Centers  
European Alzheimer's Disease Consortium



Under the auspices of :

